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ALTERATIONS OF VASCULAR ENDOTHELIAL NITRIC OXIDE
SYNTHASE ACTIVITY AND SUBSTRATE AVAILABILITY
IN CHRONIC RENAL DISEASE

Shen Xiao
(ABSTRACT)

Hypertension and other cardiovascular complications are the major causes of
hospitalization and death in patients with chronic renal diseases (CRD). Our laboratory
has previously reported that total nitric oxide (NO) production is decreased in CRD. The
overall objective in my present series of studies is to investigate the alterations of
endothelial NO system and the possible mechanisms in CRD.

In the study on CRD patients who still have residual renal function (~30% of normal
GFR), we found that the plasma from these patients did not affect L-arginine transport into
endothelial cells but significantly inhibited endothelial nitric oxide synthase (eNOS)
activity from some of these CRD patients. We established that this difference is related to
the plasma concentration of asymmetric dimethyl arginine (ADMA).

In the study of patients with end stage renal disease (ESRD), we found that plasma from
all of these patients inhibited both L-arginine transport and eNOS activity in vitro. In the
long term, inhibition of L-arginine transport into endothelial cells may cause intracellular
L-arginine deficiency which might further reduce endothelial NO synthesis. Dialysis can
partially improve the inhibition of L-arginine transport, but did not reverse the inhibition
of NOS activity. In separate studies, we found that excess L-arginine can reverse the
inhibition of NO synthesis in vitro, caused by the uremic plasma. Besides the L-arginine
analogs, we have found that urea inhibited L-arginine transport into endothelial cells both

in six hours and one week incubation, and eNOS activity after one week incubation. The
inhibition of L-arginine transport by urea is not competitive with L-arginine for the y +
transporter system and this inhibition is reversible when the uremic medium is replaced
with normal cell medium.

Finally, in our in vivo experiments, we did not find a direct inhibitory effect of uremic
levels of urea over 7 days period on NO production, nor was there any alteration of blood
pressure or renal vascular resistance in conscious rats with normal renal function.
Therefore, normal renal function is very important in maintaining and/or compensating for
the effect of high BUN on the vascular endothelial NO: L-arginine system.

PREFACE

The format of this dissertation will begin with a review of the literature pertinent to
understanding the scientific foundation on which these studies are based. The four studies
that constitute this dissertation work will then be reported in manuscript form followed by a
general unified discussion of the findings.
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Literature Review
Introduction
In the past decade, the discovery and extensive studies of the L-arginine -nitric
oxide (NO) pathway has been one of the major scientific accomplishments (Furchgott and
Zawadzki, 1980; Palmer et al., 1988; Moncada et al., 1991; Nathan and Xie, 1994; Raij
and Baylis C, 1995). NO is a gaseous free radical with only a few seconds of biological
half-life, which has been identified as playing critical roles in a remarkable array of
essential biological processes, ranging from neurotransmission, the control of vascular
tone, apoptosis to inflammation (Bredt and Snyder, 1994; Gross and Wolin, 1995). This
has changed our understanding of important aspects of the physiology and
pathophysiology of the cardiovascular, nervous and immune systems (Moncada et al.,
1991; Garthwaite et al., 1988;Rees et al., 1989; Raij and Shultz, 1993).
In 1980, Furchgott and Zawadski reported that the relaxation of arteries by
acetylcholine was dependent on the presence of an intact endothelium. In 1987, Ignarro et
al. first found that endothelium-derived relaxing factor produced and released from artery
and vein was NO. Palmer et al. demonstrated that NO could account for the endotheliumderived relaxing factor (EDRF) activity and that the precursor for its formation was the
semi-essential amino acid L-arginine. The synthesis of NO by vascular endothelium is
important in regulation of vasodilator tone and blood pressure. In vivo administration of
L-arginine analogues, such as NG-monomethyl-L-arginine (L-NMA) and NG-nitro-Larginine methyl ester (L-NAME), inhibits NO synthase, induces a maximum increase in
blood pressure of about 30mmHg in rats and rabbits, indicating that there is a basic
physiological continuous release of NO (Rees et al., 1989; Baylis et al., 1990). Besides
participating in the regulation of vascular tone, NO also affects body fluid homeostasis
(Wilcox et al., 1992; Mundel et al., 1992), platelet aggregation and adhesion (Mundel et
al., 1992; Radomski et al., 1990) and cardiac myocyte/myoblast biology (Balligand et al.,
1993;Lee et al., 1994).
NO is also one of the major cytotoxic effector molecules in mediating macrophage
cytotoxicity during host defense and immunologic reactions. Macrophages can induce
oxidative injury on tumor cells and mycobacteria that is associated with the release of NO.
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NO derived from activated macrophages is tumoricidal (Li LM et al.,1991; Lorsbach RB
et al.,1993), fungistatic and bactericidal (Nathan CF, Hibbs JJ, 1991), and inhibits viral
replication (Karupiah G et al., 1993).
NO is derived from the semi-essential amino acid L-arginine that is catalyzed by a
family of enzymes termed nitric oxide synthases (NOSs). NOSs are part of a complex
reaction system requiring molecular oxygen, reducing equivalents from reduced
nicotinamide adenine dinucleotide (NADPH) as cosubstrates, as well as several cofactors;
tetrahydrobiopterin, a cytochrome P-450 type heme moiety, calmodulin and several tightly
bound redox cofactors including flavine dinucleotide (FAD), flavine mononucleotide
(FMN). These enzymes convert arginine and oxygen into citrulline and NO (Bredt and
Snyder, 1994).
So far, three broad categories of NOS enzymes have been identified, they are
neuronal (nNOS or NOS1), inducible (iNOS or NOS2) and endothelial (eNOS or NOS3)
NOS, the genes for which are located on chromosomes 12,17 and 7 respectively (Wang
and Marsden, 1995). NOS 1,2 and 3 were originally purified from neurons, vascular
endothelium and cytokine-induced macrophages although the three isoforms are now
known to be distributed across a wide spectrum of cell types and tissues. Furthermore, a
particular type of cell can express more than one isoform of NOS (Suschek et al., 1993).
Although these isoforms have different molecular weights and variable cofactor
requirements, all are NADPH and calmodulin-dependent and contain consensus binding
sites for FAD and FMN, BH4, and a heme complex. For the two major “ constitutive”
NOS isoforms, nNOS and eNOS, exhibit strict dependency on intracellular
Ca2+/calmodulin levels. These “constitutive” enzymes generate small quantities of NO. In
contrast, iNOS appears able to bind calmodulin with extremely high affinity even at the
low intracellular Ca2+ characteristic of resting cells. Thus, iNOS is reportedly a “calciumindependent” isoform which can be induced by various cytokines and produces huge
amounts of NO for long periods of time (Nathan and Xie, 1994;Wang and Marsden,
1995). However, studies with purified, recombinant iNOS protein indicate that iNOS is
twice as active in the presence of Ca2+ as in its absence. Therefore, the common practice
of measuring L-[3H] arginine to L-[3H]citrulline conversion in the presence and absence
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of Ca2+ to distinguish iNOS from nNOS and eNOS may yield erroneous estimates of the
contributions of these isoenzymes to overall NOS activity ( Kone and Baylis, et al. 1997).
Although they are classified as constitutive enzymes, expression of nNOS and eNOS can
be regulated by specific physiological and pathophysiological stimuli such as
hemodynamic shear stress or nerve injury, and, conversely, iNOS may function as a
“constitutive” enzyme under physiological condition in some cells (Guo et al., 1995). In
addition, the same NOS isoform may play entirely distinct biological roles when
expressed in different tissues. One example of tissue-specific regulation is reflected in the
association of eNOS with different caveolin isoforms in endothelial cells versus cardiac
myocytes, the pattern of NOS activity is different in the different cell types (Feron et
al.,1996). Another example is that differential tissue-specific splicing of nNOS mRNA
generates structurally distinct protein molecules when the enzyme is expressed in neurons
versus skeletal muscle (Silvagno et al., 1996).
The biological function of NO is extremely complex: NO acts as a messenger
molecule mediating vascular relaxation, inhibiting platelet aggregation and adhesion to the
endothelium, and modulating leukocyte chemotaxis and adhesion (Moncada et al., 1991;
Bolotina et al., 1994). All these effects of NO are mediated by activation of soluble
guanylate cyclase after NO binds to its ferrous heme, resulting in increased levels of cyclic
guanosine, 3’, 5’, monophosphate (cGMP) (Moncada et al, 1991). NO also mediates
relaxation of vascular smooth muscle by directly activating calcium-dependent potassium
channels (Bolotina et al., 1994). In peripheral blood, mononuclear cells NO may act as a
signaling molecule by activating G proteins through a cGMP-independent pathway
(Lander et al. 1993). NO, when released in large quantities by the iNOS during
inflammation and injury, can inhibit enzymes such as aconitase and ribonucleotide
reductase by nitrosylation of Fe-S centers (Dimmeler et al., 1992; Stamler et al., 1992).
The actions of NO are dependent upon: (1) the amount of NO produced which is related to
the availability of its substrate L-arginine and the activity of NOS; (2) the rate of NO
inactivation by either superoxide anions and other reactive oxygen species or NO
sequestration due to binding to reactive groups such as heme groups; and (3) the
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availability of substrate such as guanylate cyclase which participates in mediating NO
actions (Raij and Baylis, 1995; Beckman and Koppenol, 1996).
As discussed above, NO production from vascular endothelial cells plays an
important role to maintain the stability of systemic and renal hemodynamics, and an
unbalanced synthesis of NO or activity of NOS can be pivotal in pathological conditions
characterized by an altered vascular tone. The synthesis of NO by endothelial cells is
catalyzed by eNOS and is promoted by certain vasodilating agents and shear stress
(Lansman, 1988; Hartmann et al., 1992). Moreover, certain cytokines including
interleukin (IL)-1 and tumor necrosis factor (TNF), that have been implicated in
pathogenesis of septic shock as well as products of Gram negative bacterialipopolysaccharide (LPS) can also induce NO synthesis catalyzed by iNOS from
endothelial cells (Lamas et al., 1991; Suttorp et al., 1993). In the kidney, NO generated by
eNOS participates in the regulation of the glomerular microcirculation by modifying the
tone of the afferent arteriole and mesangial cells and chronic NO insufficiency can cause
glomerular damage (Raij and Baylis, 1995). Many uremic syndromes such as refractory
hypertension, impairment of white blood cell function etc, in end stage renal disease, may
be related to NO insufficiency secondary to both reduced endogenous arginine generation
and/or the accumulation of endogenous NO inhibitors resulting from of the lack of
functional renal mass (Reyes et al., 1994).
In providing the scientific background and rationale for studying the alterations of
endothelial nitric oxide synthase activity and L-arginine transport in chronic renal
diseases, this review will first briefly describe the activity of nitric oxide synthase and
substrate transport in vascular endothelial cells. I will then focus on NO production and
NOS activity in renal physiology and pathophysiology, alterations of NO and NOS in
chronic renal diseases and finally discuss the potential effects of uremia and dialysis
treatment on the alterations of NOS activity and substrate availability.

Vascular endothelial L-arginine/nitric oxide synthase system.
Nitric oxide produced by vascular endothelial cells plays a crucial role in the
regulation of vascular tone, redox inflammation, growth, and the prothrombotic/
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antithrombotic properties of the vessel wall. This effect of NO is dependent on NOS
activity, substrate availability, and NO degradation.
1. Endothelial NOS activity, isoforms, and subcellular targeting: Although eNOS is
constitutively expressed in vascular endothelial cells, both in vivo and vitro studies have
demonstrated that its expression can be changed by some stimuli. In cultured cells, eNOS
expression is increased by shear stress (Nishida et al., 1992), cyclic strain (Awolesi et al.,
1995), exposure to lysophosphatidylcholine (Zembowicz et al., 1995), low concentrations of
oxidized low density lipoprotein (Hirata et al, 1995), and cyclic GMP analogs
(Ravichandran et al, 1995). In vivo, exercise training in dogs increases eNOS expression
and vasodilation in response to agonists that release endogenous NO (Sessa et al, 1994).
Several studies have also indicated that the treatment with cytokines and /or LPS enhanced
NOS activity in several kinds of endothelial cells as they did in macrophages and
hepatocytes (Yu et al., 1991 and Evans et al., 1992). In fact, an isoform of inducible NOS
was demonstrated to be co-expressed with eNOS in cytokine/LPS-treated endothelial cells.
This stimulated isoform was preceded by a several hour lag phase, existed as a soluble form,
and was inhibited by both transcription and translation inhibitors, indicating that the
increase was mediated through de novo synthesis of NOS enzyme. Its “ iNOS-like” mRNA
and protein were also detected by Northern blot and immunoblot analyses after treatment of
endothelial cells with cytokine/LPS (Wang, et al., 1994). Recently, in bovine aortic
endothelial cells, the increased NOS activity in response to tumor necrosis factor- (TNF)/LPS was localized mainly in the cytosolic fraction and was Ca2+-independent. In
contrast, NOS stimulated by interferon-,(IFN-,)/LPS was preferentially in the
membrane fraction and Ca2+-dependent, suggesting that TNF-/LPS increased iNOS-like
activity, and IFN-,/LPS increased eNOS-like activity (Kaku et al., 1997). In the intact
animal, overproduction of NO from endothelial cell iNOS (in immunologically stimulated
states) can cause marked vasorelaxation leading to hypotensive cardiovascular shock
(Griffith et al, 1992). The increases of iNOS activity from vascular endothelial cells can be
transcriptionally inhibited by glucorticoids such as dexamethasone (Simmons et al., 1996).
NO production in the endothelial cells can also be influenced by posttranslational
modifications and subcellular targeting of eNOS (Fleming et al., 1996 and Venema et al.,
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1996). These post-translational modifications include phosphorylation, N-myristoylation
and thiopalmitoylation. Several drugs and agonists that activate eNOS in blood vessels
including bradykinin, histamine, acetylcholine, ATP and hemodynamic shear stress can
stimulate endothelial cell protein tyrosine phosphorylation (Fleming et al., 1996; Venema
et al., 1996; Bowden et al., 1995 and Ayajiki et al., 1995). Studies in cultured bovine
aortic endothelial cells revealed that bradykinin causes a tyrosine phosphorylation of a 90kDa protein, eNOS -associated protein 1 which specifically interacts with eNOS and
promotes association of eNOS with the membrane cytoskeleton (Venema et al., 1996).
Conceivably, tyrosine phosporylation-dependent interaction of eNOS with the
cytoskeleton might direct NO production to specific subcellular locations. Localization of
eNOS at the cell membrane may be important for coupling extracellular signals and may
also influence delivery of NO to neighboring cells (Bredt et al., 1994 and Nathan et al.,
1994). The acylations including the myristoylation and palmitoylation are required for
efficient targeting of the enzyme to plasmalemmal caveolae (Liu et al., 1996; Shaul et al.,
1996). Caveolae are plasmalemmal microdomains that have been implicated in the
transcytosis of macromolecules, the uptake of small molecules by podocytosis, and the
compartmentalization of signaling molecules (Smart et al., 1994; Parton et al, 1994). The
latter function is particularly relevant to the regulation of eNOS activity (Shaul et al.,
1996). Numerous signaling molecules known to modulate the enzyme are concentrated in
caveolae (Smart et al., 1995). Caveolins, a family of transmembrane proteins that
constitute the principal structural and regulatory components of caveolae, have been
shown to interact functionally with several classes of signaling molecules, including
trimeric G protein subunits and the Src family of tyrosine kinases (Li et al., 1995; Li et al.,
1996). Tyrosine phosphorylation may influence not only the functional activity of eNOS,
but also its intracellular routing and interaction with other caveolin-associated proteins. Nmyristoylation is an essentially irreversible protein modification catalyzed by wellcharacterized N-myristoyltransferases, and occurs cotranslationally (following removal of
the N-terminal methionine residue) via an amide linkage of the 14-carbonsaturated fatty
acid myristate to the amino-terminal glycine within a specific N-terminal consensus
sequence (Gordon et al., 1991). By contrast, protein thiopalmitoylation is an easily
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reversible post-translational modification and involves the formation of a fatty acyl
thioester between the 16-carbon-saturated fatty acid palmitate and specific cysteine
residues in a variety of membrane-targeted signaling proteins (Resh et al., 1994;
Wedegaertner et al., 1995). Protein N-myristoylation alone appears to impart insufficient
hydrophobicity to stabilize membrane association of the modified protein. Palmitoylation
by providing additional hydrophobic interfaces, may serve to stabilize the weak membrane
association conferred by myristoylation (Peitzsch et al., 1993; Robinson et al., 1995). The
subcellular distribution for the palmitoylation-deficient eNOS closely resembles that of
agonist-treated eNOS in endothelial cells. Thus, the depalmitoylation may provide a
mechanism for agonist-stimulated release of eNOS from the cell membrane. Thus optimal
NO release from intact cells is governed by palmitoylation and the microdomain in which
the enzyme resides (Robinson et al., 1995).
In the genetic studies, the gene polymorphism of the nitric oxide synthase has been
found to be related with the pathogenesis of certain diseases. (Bonnardeaux et al., 1995).
Wang reported evidence of an association between higher susceptibility to coronary
lesions and a particular polymorphic type of eNOS locus in cigarette smokers (Wang et
al., 1996). Miyahara et al. reported cloning and structural characterization of the human
eNOS gene and suggested that a five tandem repeat in a 27bp consensus sequence in
intron 4 might serve as a genetic marker (Miyahara et al., 1994). Recently, a
polymorphism of the human eNOS gene has been identified that appeared to be linked to
hypertension (Nakayama et al., 1997) and chronic renal failure in the Japanese (Yokoyama
et al., 1998). However, whether or not changes in eNOS expression and/or function occur
as a result of such polymorphisms remains controversial and needs further study
(Bonnardeaux et al., 1995; Lacolley et al., 1998).
2. Substrate availability: L-arginine synthesis, transport, metabolism and
endogenous inhibitors: L-arginine is a substrate of NO production with a Km of
approximately 5M, it is synthesized as a product of the urea cycle and circulates in the
blood in concentrations of about 100M (Boger et al., 1997). In endothelial cells, the
concentration of L-arginine has been estimated to be several hundred to several thousand
micromolar (Arnal et al., 1995; Hecker et al., 1990). Even in the absence of extracellular
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L-arginine, the endothelium can synthesize this amino acid from L-citrulline using a novel
biosynthetic pathway (Hecker et al., 1990). Since intracellular levels of L-arginine far
exceed the Km of the NOS enzyme, its availability is (theoretically) unlikely ever to be
the rate-limiting step in the formation of NO by the endothelium in normal physiological
conditions. In isolated blood vessels, L-arginine has no effect on endothelium-dependent
vascular relaxation of aortas from normal and cholesterol-fed rabbits (Mugge et al., 1991).
However, the beneficial effects of L-arginine administration on vascular responses in vivo
have been demonstrated both in acute and chronic studies in several conditions including
hypertension and diabetes (Baylis et al., 1990; Pieper et al., 1995; Chen et al., 1993).
Following acute administration of L-arginine, Baylis, et al and others have reported that
excess L-arginine can reverse the prolonged increases in arterial blood pressure and renal
vasoconstriction caused by the L-arginine analogs in different species (Baylis et al., 1990;
Elsner et al., 1992). Chronic administration by oral feeding of L-arginine which doubles
plasma levels appears to have beneficial effects not only on vascular tone, but also on the
development of atherosclerosis in cholesterol-fed rabbits as well as on hypertension in rats
(Chen et al., 1993; Cooke et al., 1992). Therefore, L-arginine availability may be a factor
in dysfunctional endothelium where there is increased NO degradation (Morris et al.,
1995). A number of in vivo and in vitro experiments have shown that arginine availability
can be rate-limiting for the generation of NO, especially in pathophysiological conditions
such as septic shock or under the conditions of LPS or IFN stimulation. In these
situations, there is an effect not only on L-arginine synthesis, but also on the L-arginine
transport into the cells (Bogle et al., 1992; Kilburn et al, 1992).
There are two potential sources of intracellular L-arginine: de novo synthesis from
other metabolites and exogenous L-arginine taken up from the blood stream. The latter
route is particularly important in the pathophysiological overproduction of NO in patients
with septic shock (Bogle et al., 1992; McDonald et al, 1997). With regard to L-arginine
transport into the cell, there are four known L-arginine plasma membrane transport
systems. System y+ is a sodium-independent system encoded by the cationic amino acid
transporter (CAT) gene family. System y+ transports only cationic amino acids in the
absence of Na+, but at relatively high concentrations of Na+ (mM), certain neutral amino
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acids can serve as inhibitors. System B0,+, b0,+ and y+L are less specific, transporting both
cationic and neutral amino acids at physiologic concentrations . The expression of these 4
transport systems varies widely among different tissues and cell types (Thomas et al.,
1971; White 1985; Van Winke et al., 1985; Deves et al., 1992; Kilberg et al., 1993;
Malandro and Kilberg, 1996). Endothelial cells express system y+ as a primary route for
arginine transport (Green et al., 1993). Different agonists such as bradykinin can
stimulate the L-arginine transport into endothelial cells by the y+ system, which may
increase NO production (Bogle et al., 1991). Glucose and insulin can also activate the Larginine transport system (y+ system) and increase NO production (Sobrevia et al., 1996).
Regarding the modulation of L-arginine levels in the endothelium, the enzyme
arginase is present that can convert arginine to ornithine and urea, so this may affect the
availability of arginine to produce NO. Arginase I is constitutively present in endothelial
cells; arginase II can be induced in endothelial cells by LPS and -interferon (Buga et al.,
1996). Thus, induction of arginase could limit L-arginine as a substrate for NOS and may
be important in modulating cellular NO production. Of interest, arginase activity is
inhibited by N-hydroxyarginine, the intermediate of the NOS pathway (Buga et al., 1996).
Another consideration of L-arginine availability in vascular endothelial cells, is the
presence of endogenous methylarginines including L-monomethyl-L-arginine (LNMMA), NGNG-dimethyl-L-arginine (asymmetric dimethylarginine; ADMA) etc. They
are found as components of polypeptides, occur as free amino acids in brain and other
tissues, circulate in plasma, and are excreted in the urine (Vallance et al., 1992; Uneo et
al., 1992). Human endothelial cells synthesize methylarginines and ADMA is produced in
quantities that may affect NO synthesis (Fickling et al., 1993). ADMA is a potent
inhibitor of NO production from vascular endothelial cells. ADMA not only inhibits NOS
directly by competing with the L-arginine in the endothelial cell, but also inhibits the
transport of L-arginine into endothelial cells, by sharing the same transport system (y+
system) (Fickling et al., 1993). Furthermore, human endothelial cells and blood vessels
metabolize methylarginines to citrulline, in a manner consistence with the presence of the
enzyme dimethylarginine dimethylaminohydrolase (DDAH). DDAH metabolizes LNMMA and ADMA to citrulline and has been identified in certain tissues that synthesize
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NO (Macallister et al., 1994). Recently, studies reported that inhibition of DDAH could
increase the intracellular concentration of ADMA sufficiently to have a major impact on
NO production (Macallister et al., 1996). Thus, inhibiting the activity of DDAH may
provide an additional mechanism of inhibition of NOS, and changes in the activity of
DDAH could contribute to pathophysiological alternation in NO generation.
Considering substrate availability, arginine supplementation can modulate in vivo
NO production, but the mechanisms are still not clear. It is possible that the concentration
of L-arginine in microdomains of the cell (e.g., in the caveolae) is not reflect in the total
cellular concentration, and that in fact L-arginine may be limited in the immediate vicinity
of the eNOS (Michel and Feron, 1997). It is also possible that the rate of transport of Larginine into these regions may be more critical than the absolute cellular concentration
because of the subcellular localization of the eNOS protein.
3. Degradation of NO; interaction with reactive oxygen species: Nitric oxide and
superoxide are both free radicals (i.e., they contain an unpaired electron in their outer
orbit). When exposed to each other, these radicals undergo a facile radical-radical
reaction that proceeds at a rate estimated to be 6.7X109 M-1/s-1. This is much faster than
the reaction rate for superoxide with either the manganese or copper/zinc SODs (Thomson
et al., 1995). Thus, it is speculated that in a compartment in which both NO and SOD
exist, the superoxide will be preferentially react with NO rather than SOD, depending on
the relative concentrations of NO and SOD present. Studies in experimental animals and
humans have revealed that oxidative inactivation of NO may be important in some
pathophysiological conditions. For example, in cholesterol-fed rabbits, large amounts of
nitrogen oxides are released from blood vessels in an oxidatively degraded state.
Treatment of these rabbits with SOD dramatically increased endothelium-dependent
vascular relaxation, further supporting a role for superoxide (Mugge et al., 1991). In
clinical studies, infusion of ascorbic acid to inhibit the production of superoxide can
improve vascular responses to acetylcholine in cigarette smokers, diabetic individuals, and
in hypertension (Heitzer et al., 1996; Ting et al., 1995; Solzbach et al., 1997) suggest that
inhibition of NO degradation may play an important role in some pathophysiological
states.

10

Physiological roles of nitric oxide in the kidney.
1. Distribution of NOS in the kidney: the intrarenal localization of the major NOS
isoforms has been explored in detail with immunohistochemistry, in situ hybridization,
and renal microdissection combined with RT-PCR. Abundant nNOS transcripts and/or
immunoreactivity have been detected in the macula densa segment of several mammalian
species including humans. The nNOS immunoreactivity has also been detected in the
endothelium of the efferent (but not afferent) arteriole, glomerular visceral epithelium,
nerves neighboring the arcuate and interlobular arteries and pelvic epithelium, and in a
subset of mTAL (medullary thick ascending loop of Henle) cells lacking
immunoreactivity for Tamm-Horsfall protein (Wilcox et al., 1992; Bachmann et al.,
1995).
Endothelial NOS mRNA and protein have been detected in several cortical and
medullary structures. Using RT-PCR, eNOS transcripts have been found in microdissected
glomeruli, preglomerular vasculature, proximal tubules, thick ascending limbs, and
collecting ducts (Ujiie et al., 1994). However, immunohistochemical studies have shown
that eNOS immunoreactivity localized primarily to the endothelium of the glomerular
capillaries, afferent and efferent arteriole, intrarenal arteries, and medullary vasa recta. No
significant eNOS immunoreactivity was observed in any tubule segment (Bachmann et al.,
1995). The difference between the RT-PCR data and the immunohistochemical results
may reflect a greater sensitivity of the former method and/or contamination than of
microdissected tubular samples with vascular endothelial cells.
The kidney, at least in the rat, is one of the few organs that express iNOS under
basal conditions. Using competitive RT-PCR, macrophage-NOS (MAC-NOS) isoform has
been shown to be expressed at low levels in several renal tubule segments, most
abundantly in the mTAL. The vascular smooth muscle-NOS (VSM-NOS) isoform is
principally expressed constitutively in the glomeruli and interlobular and arcuate arteries
of the normal kidney (Mohaupt et al., 1994). In situ hybridization studies of normal rat
kidney with a riboprobe recognizing both MAC-NOS and VSM-NOS demonstrated that
the S3 segment of the proximal tubule, the cortical and medullary TAL, the distal
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convoluted tubule, and the cortical and inner medullary collecting duct express one or
both of these isoforms (Ahn et al., 1994). At the protein level, iNOS expression has been
demonstrated on immunoblots of renal outer and inner medullary protein (Mattson and
Higgins, 1996). iNOS expression also has been observed in rats treated with LPS or
agents to evoke immune or inflammatory injury. Under basal conditions, the two iNOS
isoform (MAC-NOS and VSM-NOS) were expressed in comparable (low) amounts in the
cortex and in the outer and inner medulla of the kidney, whereas under LPS-induced
conditions, the VSM-NOS isoform was dramatically upregulated in each renal zone
(Mohaupt et al., 1994). This differential induction of the two iNOS isoforms was also
evident in cultured glomerular mesangial cells and medullary interstitial cells treated with
tumor necrosis factor- and interferon-. (Mohaupt et al., 1994; Lau et al., 1995). Tissue
culture studies have also provided evidence for the presence of iNOS mRNA and
inducible NO production in cytokine- or cAMP-stimulated glomerular mesangial cells,
LPS and /or cytokine-stimulated proximal tubule cells, inner medullary collecting duct
cells and mTAL cells (Kunz et al., 1994; Markewitz et al., 1993; Mohaupt et al., 1995;
Kone et al., 1995).
2. Effects of nitric oxide on renal hemodynamics and glomerular microcirculation:
There is now abundant evidence that tonically generated NO plays a major role in
maintenance of renal perfusion and glomerular filtration in the normal kidney. In several
species, including humans, acute systemic NO synthesis inhibition with L-arginine
analogs produces dose-dependent increases in arterial blood pressure (BP) and renal
vascular resistance (RVR) that are reversible with excess L-arginine (Raij and Baylis,
1995; Woltz et al., 1997). When BP increases, some of the increase in RVR is
autoregulatory; however, intrarenal local and low-dose systemic NOS inhibition produces
renal vasoconstriction in the absence of increased BP (Raij and Baylis, 1995; Woltz et al.,
1997). Thus NO tonically generated within the kidney lowers RVR. The increases in RVR
due to NO synthesis inhibition causes reduction in renal plasma flow (RPF) and
glomerular filtration rate (GFR), although GFR decreases proportionately less than RPF
because filtration fraction rises ((Raij and Baylis, 1995).
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The relationship between tonically produced NO and the vasoconstrictor systems
including renin-angiotensin system (AII), sympathetic nerve system (SNS), and endothelin
(ET) is very complex and highly variable. In anesthetized surgically stressed animals, all
of the above vasoconstrictor systems are apparently active tonically in the renal
vasculature. NO attenuates their various vasoconstrictor actions within the renal
microcirculation (Kone and Baylis, 1997). When the AII system is acutely activated by
volume depletion, surgical stress, etc. or when exogenous AII levels are raised by
infusion, the renal vasoconstrictor response to acute NOS inhibition is partly due to AII
(Baylis et al., 1994; Sigmon and Beierwalters, 1993). During blockade of the reninangiotensin system, the renal vasoconstrictor responses to NOS inhibition were blunted.
These findings suggested that local AII and NO exert a modulatory influence on the renal
microvasculature (Baylis et al., 1994).
There is also controversy about the role of the SNS in the vasoconstrictor
responses to acute NOS inhibition. Some workers report that SNS inhibition (such as
ganglion blockade, adrenergic receptor inhibition etc.) has little effect on the increase in
blood pressure and RVR seen with acute NOS inhibition (Raij and Baylis, 1995). Others
claim that the hypertension and renal vasoconstriction are partly due to central and
peripheral sympathetic activation (Kumagai, et al., 1994; Cabrera and Bohr, 1995; Tseng
et al., 1996). These differences may be related to the experimental preparation and the
level of activation of the SNS (Kone and Baylis, 1997).
Endothelin is a potent vasoconstrictor peptide with widely distributed receptors
throughout the peripheral and renal vasculature. Acute systemic NOS inhibition potentates
the vasoconstrictor actions of ET and also enhances the synthesis and release of ET
(Kourembanas et al., 1993). However, studies of ET on the NO production reported that
neither acute nor chronic endothelin inhibition with either a specific ETA or a combined
ETA/ETB antagonist had any effect on either hypertension or renal injury in rats given
chronic L-NAME treatment (Zatz and Baylis, 1998). At present, the role played by ET in
the pathogenesis of hypertension in this model remains uncertain. (Zatz and Baylis, 1998).
Studies of effect of NO and other vasoactive systems on the renal hemodynamics
showed that blockade of endogenous AII system has little or no effect on NOS inhibition-
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induced renal vasoconstriction (Baylis et al., 1993; Sigmon and Beierwaltes, 1993). In the
conscious, chronically catheterized rat, where efferent renal sympathetic nerve activity is
low, renal denervation has no impact on the renal hemodynamic responses to either NOS
inhibition or NOS stimulation with L-arginine (Braith et al., 1995). In the endothelin
system, endogenous ET does contribute to control of renal vascular tone, via NO dependent
vasodilation in the rat and ET mediates some of the renal vascular responses to acute NOS
inhibition, being particularly important when a rise in renal perfusion pressure occurs.
Tonically produced NO blunts the renal vasoconstrictor responses to acutely administered
ET. The similarity between the renal vascular responses to ET administration and NOS
inhibition is not fortuitous, but in part reflects important interactions between these
vasoactive agents (Baylis, in press 1999). Micropuncture studies have also suggested that
tone in the glomerular mesangial cell is controlled by interaction between NO and both
AII and ET (De Nicola et al., 1992; Raij and Baylis, 1995), but this can not be studied in
conscious animals.
In addition to direct interactions between NO and vasoconstrictors in control of
tone, NO also controls glomerular hemodynamics indirectly by contributing to the
tubuloglomerular feedback (TGF) response, and by modulating renin release from
granular cells of the juxtaglomerular apparatus (Raij and Baylis, 1995; Navar et al., 1996).
When TGF is operating an increase in tubular fluid reabsorption by the macula densa
promotes vasoconstriction of the neighboring (parent) afferent arteriole, thereby reducing
glomerular capillary pressure and GFR and restoring tubular flow rate to a pre-set value.
NOS is abundant at the juxtaglomerular apparatus, and NO generated within the macula
densa (from nNOS) may control glomerular hemodynamics by providing vasodilatory
attenuation to offset this increase in afferent arteriolar resistance and to decrease the
sensitivity of the tubuloglomerular feedback system (Wilcox et al, 1992; Thorup and
Persson, 1994). However, whether NO plays a direct regulatory role or a more permissive
role in the control of renin secretion is very complicated and remains to be answered. NO
appears as a tonic enhancer of renin secretion, acting via inhibition of cAMP degradation
through the action of cGMP. Depending on as yet unknown factors, the stimulatory effect
of NO on renin secretion may also switch to an inhibitory one that is compatible with the
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inhibition of renin secretion by cGMP-dependent protein kinase activity (Kurtz and
Wagner, 1998).
NO also plays an important role in the control of renal medullary blood flow,
medullary oxygenation, and the blood pressure -induced vasodilation of the papillary
circulation (Patel et al., 1994; Hall et al., 1996 and Brezis and Rosen, 1996). Acute NOS
inhibition, through reductions in medullary blood flow, blunts the pressure-natriuresis
relationship and promotes sodium retention (Fenoy et al., 1995). The nNOS appears to be
the major NOS isoform responsible for NO production in the renal medulla. In rats fed a
high sodium intake, selective inhibition of nNOS activity by continuous infusion of
antisense oligonucleotides or 7-nitroindazole into the renal medullary interstitium,
decreased total renal medullary NOS by ~35% and increased mean arterial pressure by ~
15 mmHg (Mattson and Bellehumeur, 1996 ). Chronic NOS blockade results in a resetting
of the pressure-natriuresis relationship, apparently related to overexpression of
vasoconstrictor systems, that results in continued sodium retention despite hypertension
(Hu and Manning, 1995; Guarasci and Kline, 1996).
3. Effects of NO on renal tubular function: In “in vivo” studies, administration of low
doses of NOS inhibitors at concentrations that do not alter glomerular or systemic
hemodynamics, impairs urinary sodium excretion (Shultz and Tolins, 1993; Bech et al.,
1996) and infusion of NO donors induce natriuresis (Majid et al., 1993). In rats, when the
intrarenal perfusion pressure is kept constant at basal levels with a suprarenal aortic snare,
acute, intrarenal arterial infusion of L-NMMA reduced urinary sodium excretion by 50%
(Shultz and Tolins, 1993). In chronic studies, conscious dogs infused with a low dose of
L-NAME for 5 days exhibit ~40% reduction in urinary sodium excretion without any
changes of mean arterial pressure (Salazar et al., 1993). Similarly, in humans chronic LNAME administration resulted in a 40% reduction in fractional excretion of sodium (Bech
et al., 1996). Acute sodium infusion increases urinary NOx (nitrate and nitrite) excretion,
which reflects an increase of NO synthesis, and NOS inhibition, inhibited the natriuretic
response to acute volume expansion (Tolins et al., 1994). Chronic (2 weeks) high salt
intake in rats results in increased urinary NOx production in parallel with an increment in
sodium excretion (Tolins and Shultz, 1994). Also, in the model of chronic nitric oxide
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blockade, salt dependence is a function of the inhibitor dose, and renal injury varies
directly with the level of salt intake (Yamada et al., 1996). So, all the above data suggest
that basal NO synthesis plays an important role in the renal regulation of the extracellular
fluid volume and blood pressure, and that inhibition of NO synthesis reduces the adaptive
increase in urinary sodium excretion and further prolong the increases in the extracellular
fluid volume.
In vitro studies have shown that NO can exert direct effects on specific ion
transport and may further influence overall acid-base and electrolyte balance. NO and NO
donors dramatically inhibited H+-adenosine triphosphatase (ATPase) activity (Tojo et al.,
1994), Na+ reabsorption (Stoos et al., 1995), and antidiuretic hormone (ADH)- stimulated
osmotic water permeability in the cortical collecting duct (CCD) (Garcia et al., 1996), net
Cl- reabsorption in the mTAL (Stoos and Garvin, 1996), Na+ - H+ exchange in the
proximal tubule (Roczniak and Burns, 1996), and N+ - K+ ATPase activity in renal
medullary slices (McKee et al., 1994) and in proximal tubule (Guzman et al., 1995) and
mTAL cell lines ( Kone and Higham, 1996 ). Patch clamp studies found that NO also
participates in K+ recycling at the basolateral side of the CCD by activating the
basolateral low-conductance K+ channel (Lu and Wang, 1996). The effects of NO on
CCD Na+ reabsorption, ADH-stimulated water permeability, and K+ channel activity, as
well as proximal tubule Na+ - H+ exchange appear to be mediated via cGMP-dependent
mechanisms. For the ADH -stimulated water permeability in the CCD, the NO-cGMP
dependent mechanism may further influence the cAMP production via cGMP-dependent
protein kinase, and cAMP is the transducer of the antidiuretic hormone effect (Garcia et al,
1996). Studies in an iNOS-transfected mTAL cell line have also shown that tonic NO
production constrains Na+ - K+ - ATPase 1 subunit gene expression and Na+ - K+ ATPase activity, the principal driving force for Na reabsorption (Kone and Higham,
1996).

Pathophysiological roles of nitric oxide in the kidney.
1. IMMUNOLOGICALLY MEDIATED Glomerular and tubulointerstitial diseases:
In animal models, NO is involved in the induction, progression, and in some cases,
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protection against several types of experimental glomerulonephritis and tubulointerstitial
disease including experimental immune complex glomerulonephritis, nephrotoxic
nephritis, anti-Thy-1 glomerulonephritis, autoimmune Heymann nephritis, unilateral
ureteral obstruction, etc. In some situations, during glomerular inflammation, NO and
cytokines, such as interleukin-1, TNF-, and IL-6 from glomerular endothelial cells,
infiltrating macrophages, and activated mesangial cells promote glomerular damage
(Jansen et al., 1994; Goto et al., 1995; Waddington et al., 1996). In glomeruli harvested
from rats early in the course of experimental immune complex glomerulonephritis and
nephrotoxic nephritis, increased nitrite production and iNOS mRNA expression have been
reported (Jansen et al., 1996; Cook et al., 1994). In MRL-lpr/lpr mice, which
spontaneously develop an immune complex glomerulonephritis, high levels of urinary
nitrite/nitrate and increments in glomerular iNOS mRNA and protein occur, as the disease
progresses. Treatment of these mice with NOS inhibitors prevented clinical
glomerulonephritis without altering serum levels of anti-DNA antibodies, implicating NO
as a important mediator of the inflammatory glomerular lesion and indicating that iNOSgenerated NO production was not simply the result of nonspecific immune activation
(Weinberg et al., 1994). Similarly, in the early stage of anti-Thy-1 glomerulonephritis,
systemic NOS inhibition dramatically reduced mesangial cell injury and extracellular
matrix deposition, suggesting that NO participates in cytotoxicity to mesangial cells
(Narita et al., 1995). On the other hand, NOS inhibition exacerbated proteinuria and
glomerular injury in rats with nephrotoxic serum nephritis and autoimmune Heymann
nephritis (Jansen et al., 1994), suggesting that NO played a protective role in these
models. Moreover, depletion of plasma arginine levels by systemic arginase
administration early in the course of nephrotoxic serum nephritis promoted
intraglomerular thrombosis and greater glomerular injury (Waddington et al., 1996). Also,
in rats with unilateral ureteral obstruction, treatment with L-arginine reduced
monocyte/macrophage infiltration and interstitial expression of collagen IV, -smooth
muscle actin, and tissue inhibitor of metalloproteinase-1 mRNA in the contralateral
unobstructed kidney compared with vehicle-treated rats (Morrissey et al., 1996). The two
faces of iNOS-generated NO in glomerular inflammation are not clear. The possible
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proinflammatory effects of NO in these settings may include its ability to increase
vascular permeability in inflamed tissues. The secondary generation of the destructive
peroxynitrite and hydroxyl radical, the induction of the inflammatory cytokines, TNF-,
IL-1, and the amplification of IL-1-induced prostaglandin E2 production are also likely
to be damaging. The protective roles of NO may include reduction of vasoconstriction,
platelet aggregation and glomerular thrombosis, inhibition of leukocyte recruitment and
scavenging of free radicals. Also, both in vitro and in vivo studies suggest that iNOSgenerated NO may be antifibrotic and therefore may serve to limit the severity of
glomerular and interstitial fibrosis (Kone, 1997). Therefore, manipulation of the iNOS
levels may drastically alter the course of experimental renal disease. The time courses of
renal diseases with respect to the changes of NOS are not clear. In the early stage, the
increase in NO (via iNOS) causes injury and the decrease NO generation secondly to
disease process produces further injury.
In the human renal diseases, the alterations and function of NO have been studied
in many kinds of renal diseases such as idiopathic nephrotic syndrome with minimal
change disease, focal segmental glomerulosclerosis, immunoglobulin A (Ig A)
nephropathy, non-IgA mesangial proliferative glomerulonephritis and urinary tract
infections. iNOS has been detected in renal biopsies from patients with IgA nephropathy,
non-Ig A nephropathy mesangial proliferative glomerulonephritis, but not in normal
kidney tissue removed during surgery for renal cancer ( Kashem et al., 1996).
Immunohistochemical analysis of biopsy samples from the nephritic kidneys revealed that
the iNOS-expressing cells were predominantly infiltrating monocytes and macrophages in
the tubulointerstitial areas, where IFN- and TNF- mRNA expression were also
prominent. Clinical and histologic data showed that decreased renal function and
tubulointerstitial damage were greater in the iNOS-expressing patients (Kashem et al.,
1996). It has also been found that NO excretion was higher in the patients with idiopathic
nephrotic syndrome with minimal change disease than in IgA nephropathy and focal
segmental glomerularsclerosis. However, the exact roles of NO in these different renal
diseases are not clear (Trachtman et al., 1996). In addition, the elevated levels of iNOS
activity and protein have been found in neutrophils isolated from the urine of patients with
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urinary tract infections. The enhanced expression of urinary neutrophil iNOS activity was
sustained through 6 to 10 days of antibiotic treatment, suggesting potential antimicrobial
and proinflammatory roles of NO in this setting (Wheeler et al., 1997).
The source of iNOS activity in inflamed renal tissues is in part from infiltrating
macrophages (Kashem et al., 1996) but in vitro studies showed that glomerular mesangial
cells and tubulointerstitial cells respond to immune stimuli by synthesizing large amounts
of iNOS and NO (Kunz et al., 1994; Mohaupt et al., 1994; Shultz et al., 1994). And once
activated by immune stimuli, mesangial cells have the potential to produce IL-1 and
TNF- (Noronha et al., 1993), two key molecules that help to perpetuate the formation of
iNOS and other inflammatory mediators. IL-1 and cAMP activate iNOS gene
transcription via separate signaling pathways that can be inhibited by dexamethasone
(Kunz et al., 1994) and pyrrolidine dithiocarbamate, (Eberhardt et al., 1994). IL- induces
NF-B in mesangial cells, which trans-activate the iNOS gene. Pyrrolidine
dithiocarbamate partially blocked IL-1, but not cAMP-induced iNOS expression,
indicating differences in iNOS trans activation by these two pathways and that
transcription factors other than NF-B also contribute to iNOS induction by each agent
(Eberhardt et al., 1994). These pathways show the complexity of iNOS gene control in
these cells.
2. Acute renal failure: In acute renal failure, the roles of NO are ambiguous. In vitro
studies shown that NO can improve the renal tubular epithelial and vascular endothelial
regeneration after injury due to postischemic acute renal failure (Noiri et al., 1997). In
contrast, the nonselective NOS inhibitors can protect renal cortical tubules against hypoxic
injury (Yamada et al., 1996), and selective inhibition of iNOS with antisense
oligodeoxynucleotides protected renal epithelial cells from oxidative cellular injury
(Peresleni et al., 1996), suggesting NO-mediated cytotoxicity in some settings. In “invivo” studies, nonselective NOS blockade exacerbated mTAL injury in renal failure
induced by radiocontrast agents (Agmon et al., 1994). In contrast, systemic administration
of antisense oligodeoxynucleotides to block iNOS protein induction in rat renal tubules,
reduced tubular necrosis and preserved renal function after an ischemic insult (Noiri et al.,
1996). These opposing roles of NO in acute renal failure may be related to the different
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NOS and different phases of the disease for NO production. Reduced endothelium derived
NO production causes vasoconstriction and worsens ischemia. Increased NO production
from iNOS exacerbates the injurious effect of ischemia on these cells, so any therapeutic
intervention designed to modulate NO in acute renal failure requires selective alterations
of NO production within endothelium (eNOS) and /or renal tubular cells (iNOS)
(Lieberthal, 1997).
3. Hypertension: NO deficiency may cause maladaptive renal sodium handling, which
may be implicated in the pathogenesis of salt-sensitive hypertension. Administration of Larginine, but not D-arginine (the inert isomer), prevents hypertension and normalizes
pressure natriuresis and altered renal tubular transport in the salt-sensitive Dahl-Rapp rat
(Chen and Sanders, 1991; Chen and Sanders, 1993;Kirchner et al., 1995). Increased
dietary NaCl stimulated NO production in the salt-resistant rat, but not the salt-sensitive
rat, unless L-arginine was provided. In a similar fashion, salt feeding and nitroprusside
infusion caused less of an increase in cGMP excretion in salt-sensitive rats than in saltresistant rats (Simchon et al., 1996), and the kidneys of salt-sensitive rats exhibited lower
levels of calcium-dependent NOS activity than did salt-resistant rats (Ikeda et al., 1995).
These data suggest that the salt-sensitive rats have a genetic defect in nitrovasodilation
related to the role of NO in regulating extracellular fluid volume. In normal animals,
chronic NOS inhibition leads to volume-dependent hypertension. A low level of NOS
inhibition produced a vasoconstrictor response that is confined to the kidney (Baylis et al.,
1996; Walder et al., 1991). These low doses produce no pressor effect in rats or dogs on
normal salt diet, but elevations in blood pressure do occur with high salt intake by a
volume-dependent effect (Lahera et al., 1992; Yamada et al., 1996). The volume
dependent hypertension is only evident during selective, intrarenal NOS inhibition, since
widespread NOS inhibition causes an immediate vasoconstriction that leads to
hypertension in the absence of volume expansion and even during volume contraction (Hu
et al., 1994; Mattson et al., 1994; Qiu and Baylis, 1994). In man, the basal NOS activity,
tested by acute NOS blockade, is impaired in essential hypertension. The degree of
impairment is inversely correlated with the blood pressure (Calver, et al., 1992; Panza, et
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al., 1993), suggested that NO deficiency may play a pathogenic role in hypertensive
patients.
NO deficiency-induced hypertension may result from the reductions of NO
synthesis from a variety of cells and NOS isoforms. Hypertension occurs in eNOS
knockout mice but not in the nNOS knockout mice suggesting that NO from eNOS is of
primary importance in blood pressure regulation. In human studies, some studies indicate
that there is no genetic linkage between eNOS and essential hypertension (Bonnardeaux et
al., 1995; Hunt et al., 1996). However, recently, a polymorphism of human eNOS gene
has been identified that appears to be linked to hypertension (Nakayama, et al, 1997;
Tsukada, et al., 1998). The data from knockout studies are hard to interpret. In the “nNOS
ko” mouse there was no change in BP. In contrast, functional studies with
pharmacological or antisense nNOS inhibition suggest that nNOS plays an important role
in blood pressure control, possibly by modulation of the sympathetic envois system. (Raij
and Baylis, 1995; Santymire et al, 1996; Tseng et al., 1996). There is also some functional
evidence that a defect in NO originating from an iNOS is associated with salt-dependent
hypertension in the Dahl-Rapp rat (Chen and Sanders, 1993). However, chronic iNOS
inhibition with aminoguanidine in the rat on a normal dietary salt intake had no effect on
blood pressure or renal hemodynamics (Qiu and Baylis, 1994), and chronic inhibition of
iNOS in rats on high-salt diet leads to a paradoxical hypotension (Bloch, et al., 1996).
Therefore, the possible role of NO originating from rat iNOS isoforms in response to
changes in salt intake remains to be further Elucidated.

Alterations of NO in the chronic renal failure (CRF).
1.Experimental Model: The pattern of NO synthesis in experimental uremic model
appears to be complex. Most studies have focused on the experimental model of CRF
obtained in rats by extensive renal mass reduction (RMR) due to ablation
(uninephrectomy) and infarction (of 2/3rds of the contralateral kidney). These animals
develop systemic hypertension and exhibit a decrease in both GFR and RBF, despite an
initial adaptive increase in single-nephron GFR and plasma flow per nephron (Anderson et
al., 1985). Animals with RMR also develop severe proteinuria and structural changes in
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the kidney, including glomerulosclerosis, which eventually leads to renal insufficiency
(Anderson et al., 1985). In this kind of CRF model, oral supplementation of L-arginine
had a protective effect on urinary protein excretion and renal function (Ashab et al., 1995).
In other studies, dietary supplementation with L-arginine for 6 weeks reduced
glomerulosclerosis; this beneficial effect of L-arginine appeared to result from a reduction
in glomerular capillary pressure and efferent arteriolar resistance (Reyes et al., 1992). It
has also been found that the NOS activity of the kidney (by measuring the ex vivo
conversion of L-arginine to citrulline) was markedly lower in RMR rats than in normal.
Consistent with these results, urinary excretion of NOx (nitrate and nitrite) was
significantly reduced in rats with RMR compared to control animals (Zappella et al., 1996;
Aiello et al., 1997), suggesting a reduction in total NO production.
Using two histochemical approaches to locate NOS catalytic activity (NADPHdiaphorase) or NOS isoenzyme expression (immunoperoxidase): 1) NADPH-diaphorase
decreased suggesting a progressive loss of renal NOS activity in RMR rats in all the
structures examined including glomeruli, proximal tubules, and collecting duct (Aiello et
al., 1997); 2) A progressive decrease of iNOS immunostaining occurred which
corresponded with the loss of the NADPH-diaphorase activity, indicating that some of the
reduced NOS activity in RMR was likely due to a decrease in iNOS enzyme content
(Aiello et al., 1997). In contrast to iNOS, eNOS staining was similar in RMR and control
kidneys. However, in RMR rats, the eNOS signal was reduced in glomeruli affected by
sclerosis, possibly because of loss of functional endothelium (Aiello et al., 1997). The
possible causes of progressive loss of iNOS in this model may relate to the increase of
some inflammatory mediators, such as platelet-derived growth factor (PDGF) and
transforming growth factor  (TGF-). Soon after surgical ablation of renal mass, these
inflammatory factors are formed in excessive amounts in glomeruli (Floege et al., 1992;
Lee et al., 1995). PDGF and TGF are both potent inhibitors of NO synthesis and dose
dependently block IL-1-induced iNOS mRNA in rat mesangial cells (Ketteler et al.,
1994). A recent study reported that using CRF model produced by infarction/ablation is
associated with an exuberant hypertension, which might independently stimulate the Larginine-NO pathway. When an equivalent renal reduction is produced by surgical
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resection of the upper and lower thirds of one kidney, followed by contralateral
nephrectomy, a slowly developing CRF occurs with only a mild hypertension. In this
model, both the urinary excretion of NOx, NOS activity and NOS protein of eNOS and
iNOS from thoracic aorta and the remnant kidney, was downregulated. These changes
may relate to the excess secretion of parathyroid hormone in chronic renal failure and can
be reversed by calcium channel blockade and parathyroidectomy (Vaziri et al., 1998).
These workers also reported that decreased NO production and increased oxygen free
radical activity are responsible for the pathogenesis of uremic hypertension (Vaziri et al.,
1998). Further study is necessary to determine if the RMR model is associated with
endothelial dysfunction, as is seen in human uremia.
2. Human studies: Although several groups have focused on NOS activity and NO
production in chronic renal failure and end stage renal disease, the results from in vivo
and in vitro experiments are equivocal.
In vivo studies: Patients with end stage renal disease (ESRD) on regular
hemodialysis often have a history of bleeding symptoms and variably prolonged skin
bleeding times. In these patients, the plasma L-arginine was higher than in controls.
Uremic platelets generate more NO than control platelets, and intraplatelet levels of cyclic
GMP (the NO second messenger) were also higher in uremic than in control platelets,
which therefore suggested that nitric oxide synthesis is enhanced in uremia (Noris et al.,
1993). Another study on the effects on NOS activity and renal function of oral
supplementation with arginine over a 6-month period in patients with moderate renal
failure (inulin clearance=20-60ml/min) shown that the increment in plasma arginine was
paralleled by a marked increase in urinary nitrates. The increase in NO production was
associated with no variation in either GFR or proteinuria, thus, it was concluded that in
patients with moderate CRF, NO production is normal, and the chronic arginine
supplementation while being effective in enhancing NO generation, does not affect the
renal outcome (Cianciaruso et al., 1996). However, in contrast to these studies, recently,
several in vivo studies have reported NO deficiency in chronic renal failure. Studies on
NO production in 83 consecutive patients with chronic renal failure, measuring plasma
and urine NOx (nitrate and nitrite) have found that the daily urinary NO production was
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significantly lower in patients with moderate (creatinine clearance is between 3060ml/min/1.73m2) and severe (creatinine clearance <30ml/min/1.73m2 and without
dialysis treatment) renal failure as compared with those with mild (creatinine clearance >
60ml/min/1.73m2) and normal controls. The lowest values were found in the severe renal
failure group. The NO excretion directly correlated with the creatinine clearance and
inversely correlated with the serum creatinine level. The plasma NO concentration was no
different between the three chronic renal failure groups, but was higher than in the
controls. Plasma NO in renal failure patients did not correlate with the creatinine clearance
or serum creatinine levels (Blum et al., 1998). Of importance, however, there was no
dietary NOX control in this study. A recent study from our laboratory has reported that, in
subjects on a controlled low nitrate diet for 48 hours, the total NO production (by
measuring NOX output) was significantly reduced in hemodialysis and peritoneal dialysis
patients as compared with controls. Controls also had significantly greater cyclic GMP
excretion than peritoneal dialysis patients, which correlated with normal NO production in
controls and a low NO state in the patients. Systolic blood pressure was lower in controls
than in hemodialysis patients even after a dialysis treatment. These findings suggested that
NO production is low in the patients with end stage renal failure and the hypertension in
these patients may reflect NO deficiency, in addition to fluid overload (Schmidt et al.,
1999). Also, in patients on hemodialysis, acute L-arginine, but not D-arginine, infusion
could correct renal failure-associated endothelial dysfunction by competing with
endogenous inhibitors of nitric oxide synthase that accumulated in EDRF (Hand et al.,
1998).
Several physiological factors can interfere with both the NOx levels in plasma and
urine. These include the dietary intake, inhalation of NO in polluted air (minor source),
some physiological activities such as heavy exercise (heavy exercise is associated with
increased NO generation and increased NOx excretion via the sweat). Dialysis treatments
( by alterations of the body volume) and some drugs as well as acid pH and vitamin C can
also affect the NOx measurement (Baylis and Vallance, 1998). There are also problems
with the use of cGMP as a surrogate measure of the NO system since cGMP is also a
second messenger of other endogenous vasoactive substances such as atrial natriuretic

24

peptide (Moncada et al., 1991). Furthermore, the tissue contents of cGMP are more
important and may be different from the plasma concentration of cGMP ( Arnal et al.,
1992). Thus in vivo studies on NO production in CRF patients are limited to some extent.
In vitro studies: Studies of nitric oxide synthase activity in human umbilical vein
endothelial cells (HUVEC) incubated with uremic plasma indicate that the plasma from
uremic patients with a history of bleeding symptoms and variably prolonged skin bleeding
time can potently increase NOS activity in this type of endothelial cell. This increase can
be further amplified by the addition of endotoxin and interferon . These data suggested
that the nitric oxide synthesis was enhanced in uremia (Noris et al., 1993). In contrast to
this study, the accumulation of some endogenous L-arginine analogs including L-NMA
and ADMA which are very potent NOS inhibitors have been found in uremic patients. In
vitro experiments show that these substance can significantly inhibit NOS activity and NO
production in different kinds of vascular endothelial cells (Vallance et al., 1992; Ribeiro et
al., 1996). It has also been found that the high plasma concentration of urea in uremic
patients can significantly inhibit the NOS activity and NO production in macrophages
(RAW 264.7 cells) stimulated by bacterial lipopolysaccharide. The mRNA for this
inducible NOS was not inhibited by urea suggesting inhibition of inducible NOS by a
posttranscriptional mechanism, and that this may be important in macrophage dysfunction
in uremia (Prabhakar et al., 1997). Another in vitro study of NOS activity and NO
production in ESRD has reported that most (79%) of uremic plasma inhibits NOS activity
in tEND.1 cell line (a type of murine transformed endothelial cell that expresses both
eNOS and iNOS isoform) and in cytokine induced J774 cell line (a type of murine
macrophage line that only expresses iNOS isoform), but were ineffective in human
umbilical vein endothelial cells (HUVEC, which only express eNOS). Approximately
twenty percent of plasma samples activated NOS activity in tEnd.1 and in J774 cells, but
not in HUVEC, suggesting the presence of molecule(s) which influence iNOS. The effect
of plasma was not dependent on the type of hemodialysis treatment. It was also reported
that plasma from many patients with moderate renal failure also inhibited NOS activity in
tEnd.1, suggesting that the accumulation of molecules that affecting NOS was caused by
the renal failure rather than the hemodialytic treatment. Finally, it was concluded that the
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effect of end stage uremic plasma on NOS activity is derived from the balance between
inhibitors and activators (Arese et al., 1995).
Recently a genetic study reported that there is a significant increase of  allele of
eNOS in end-stage renal disease patients (Yokoyama et al., 1998). Since the  allele of
eNOS is a risk factor for coronary artery stenosis (Wang et al., 1996), the eNOS gene
polymorphisms may have some relevance to the prevalence of chronic renal diseases. This
indicated a possibility that these polymorphisms may be involved in the pathophysiology
of the progression of chronic renal diseases. At this time the modulation of NO synthesis
by plasma of CRF patients remains controversial.
3. Effects of dialysis on NO production in CRF patients: Dialysis is one of the major
renal replacement therapies for treating the patients with end stage renal failure. Many
complications occur during dialysis especially in hemodialysis such as dialysis related
acetate intolerance (expressed with smooth muscle relaxation and extreme vasodilation)
which relates to the abnormal production of the NO. However, the exact alterations of NO
production from dialysis are not clear and depend on the different dialysis regiments with
different materials of the dialyzers and different dialysates.
Effects of dialyzer membranes. It is reported that with complement-activating
cuprophan dialysis membrane, stimulation can occur of IL-1, tumor necrosis factor-
and other cytokines from macrophages. These cytokines then can induce the expression of
iNOS from smooth muscle cells and endothelial cells, and cause excessive production of
NO (Haeffner-Cavaillon et al., 1989; Schindler et al., 1993). However, with complementbiocompatible polysulfone and polyacrylonitrile membranes, the data are conflicting.
Some studies showed stimulation of IL-1 generation during dialysis (Herbelin et al.,
1990; Carozzi et al., 1992), whereas others found no intradialytic increases (Schindler et
al., 1993; Descamps-Latscha, et al., 1995).
Effects of dialysate: Dialysate plays a major role in influencing the release of IL-
and other cytokines. Studies with different dialysates including acetate (38 mM acetate),
bicarbonate with 4mM acetate and acetate free buffer have showed that acetate can lead to
3X increase in NOS activity in transformed endothelial cells (murine endothelioma cell
line T End.1). In contrast, only a small increase in NOS activity was seen with
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bicarbonate dialysate and no changes in NOS activity in acetate free buffer. The mRNA
encoding for inducible NOS was highly expressed in endothelial cells incubated with
acetate buffer and also with acetate in bicarbonate dialysate. The endothelial cell
proliferative index was depressed by acetate, and tumor necrosis factor synthesis was
increased compared with acetate-free buffer (Amore et al., 1997). Human plasma from
uremic patients treated with dialysis with acetate dialysate can also significantly increase
NOS activity in human umbilical vein endothelial cells. In contrast, plasma from patients
treated with bicarbonate dialysate or acetate free buffer did not affect NOS activity in
endothelial cells (Noris et al., 1998). In uremic patients, common symptoms include
interdialytic hypertension and dialysis hypotension; this may relate to the dysfunction of
baroreceptor sensitivity, in uremia. Injury to endothelial cells by uremia would cause
defective local NO production and then blunt baroreceptor sensitivity. Impaired
baroreceptor function, via failure to appropriately sense blood pressure alterations, results
in inappropriate increases in central sympathetic outflow and contribute to increases in
mean arterial pressure in uremia with interdialytic hypertension. Blunted baroreceptor
function in uremia may also contribute to vascular instability and dialysis-related
hypotension and an inability to defend against acute hemodialysis-induced blood pressure
changes (Blantz et al., 1996).
In summary, in CRF, several factors may affect NO production. 1). Systemic
hypertension and / or atherosclerotic changes may diminish endothelial generation of
nitric oxide (acute); 2). A reduction in functional renal mass may limit the arginine supply
by reduced renal synthesis from citrulline; 3). Elevated cytokine production may
chronically induce elevated iNOS activity; 4). Generation and retention of arginine
analogs may act as competitive inhibitors of nitric oxide synthase; and 5) Oxidation
reduction status of cells may dictate the physical forms of NO and thereby
enzyme/receptor targets regulating function activity (Blantz et al., 1996). However, what
the exact alterations of endothelial nitric oxide synthase activity, substrate availability and
NO production in chronic renal diseases, and how these changes affect the progress of
chronic renal diseases, uremic syndromes and dialysis treatment need to be further
studied.
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OBJECTIVES

As discussed above, hypertension is one of the major complications in chronic
renal disease (CRD) and is difficult to control. Vascular endothelial cell derived NO plays
an important role in maintaining blood pressure and vascular tone. Clinical studies have
shown that total NO production is decreased in CRD patients. Therefore, the overall
objective in my study is to determine if the reduction of total NO production in CRD,
measured as reduced NOx output, reflects insufficiency of eNOS activity and/or substrate
availability in endothelial cells and is related to hypertension in CRD. Furthermore, I have
also studied the mechanisms of the alterations of eNOS activity and substrate availability
in vascular endothelial cells due to the metabolic disorders, body fluid overload and
waste/toxins accumulation in conditions of chronic renal diseases. This series of studies
include the following aspects:
1. Study of the effects of plasma from CRD patients who still have residual renal
function on eNOS activity and substrate availability (L-arginine transport) in endothelial
cells. These patients still have part of their renal function and can maintain their basic
metabolism. However, the morbidity of hypertension in these patients is already
significantly higher than in normal, and hypertension in CRD is a very important risk
factor in accelerated deterioration of renal function. To study the mechanisms of
hypertension and changes of NO production in these patients, the plasma concentration of
L-arginine analogues, asymmetric dimethyl L-arginine (ADMA) and symmetric dimethyl
L-arginine (SDMA) were also measured and their effects on NOS activity were also
examined.
2. Study of effects of plasma from patients with end stage renal disease on eNOS
activity and substrate availability in the endothelial cells. In this condition, patients almost
totally lose their renal function and require dialysis (peritoneal dialysis or hemodialysis) to
survive. The prevalence of hypertension in these patients reaches ~90-100%. Some of
these patients show a refractory hypertension after getting “adequate dialysis treatment”,
and without body fluid overload. The effect of dialysis on constitutive endothelial NOS
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activity, inducible NOS activity and L-arginine transport were also investigated in these
patients.
3. Study of effect of urea on NOS activity and L-arginine transport in endothelial
cells. Urea is an end product of protein metabolism. The plasma concentration of BUN
increased three to ten times in CRD or ESRD compared to normals. Urea has been
previously found to inhibit the iNOS activity and NO production in macrophages.
Therefore, high BUN may also be involved in the inhibition of eNOS activity and/or
substrate availability in endothelial cells and be related to hypertension in CRD patients.
This study included short term and long term incubation with endothelial cells to study the
effect of urea on NOS activity and L-arginine transport.
4. Study of the effect of uremic levels of BUN on blood pressure, renal function
and NO production in chronic conscious rats with normal renal function. In these in vivo
experiments, the functional effects of high BUN were examined and compared to the
findings in cell culture experiments.
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GENERAL METHODS
1. Primary vascular endothelial cell culture: Different vascular endothelial cells have
been used in these studies. These cells include human dermal microvascular endothelial
cells (HDMEC), human glomerular endothelial cells (HGEC) and bovine aortic
endothelial cells (BAEC). HDMEC and endothelium growth medium (EGM-MV) were
obtained from Clonetics Corporation (San Diego, CA). HGEC were obtained from Cell
System Corp. (Kirkland, WA). These two human endothelial cell types were cultured in
EGM-MV containing 5% fetal bovine serum, 10ng/ml epidermal growth factor, 1g/ml
hydrocortisone, 50g/ml gentamicin sulfate, 50g/ml amphotericin and 3g/ml bovine
brain extracts. BAEC were isolated by us in primary culture from bovine thoracic aortas
harvested from the local abattoir according to the established methods (Buckley, et al.
1991) with some modifications. Briefly, bovine thoracic aortic segments were obtained
from bovine aorta and put it into sterile PBS solution containing 100u /ml penicillin and
100ug/ml streptomycin to clean, then placed into PBS solution containing 20ug/ml
gentamicin at a room temperature for one hour. After that, the tissue was cut and opened
and put the lumen side (endothelial side) faced down into a sterile petri dish containing
1mg/ml collagenase (type 1A collagenase, Sigma) with 0.1% bovine serum albumin in
PBS incubated 25 min in 370C incubator. Tissue was then turned over and scraped slightly
to remove the endothelium. The cell supernate was harvested to 12ml sterile tube with 6ml
of DMEM-10 medium containing 20% bovine serum, 100ug/ml streptomycin, 100u/ml
penicillin, 10ug/ml gentamicin, 0.25ug/ml amphotericin B and 0.25ug/ml sodium
desoxycholate. The cell solutions were then centrifuged at 200g for 5 min to pellet the
cells. Cells were suspended in another sterile tube with 5ml DMEM-10 medium and then
cultured with DMEM-10 medium in T-25 flasks with 2% gelatin. When confluent, the
cells were split into T-75 flasks.
All of these three kinds of endothelial cells are maintained in T-75 flasks and
incubated at 37 0C with 5% CO2 and had tested positive for Factor VIII and acetylated low
density lipoprotein (LDL) uptake and negative for smooth muscle alpha actin confirming
that they are pure endothelial cells. HDMEC and HGEC were studied between passage 5
and 8, BAEC were studied between passage 3-5.
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2. Conscious, chronically catheterized rat preparation: Male Sprague-Dawley rats (350450g) were obtained from Harlen Sprague-Dawley, Indianapolis, Inc. The procedure for
the rat catheterization was carried out under full sterile condition and general anesthesia,
using the short-acting barbiturate, Brevital (Eli Lilly & Co., Indianapolis). The induction
dose was 50mg/kg ip, and thereafter, 5-10mg/kg was given iv as required. Tygon catheters
were placed in the abdominal aorta and inferior vena cava through the left femoral artery
and vein, threaded under the skin by 16-G trocar and exteriorized at the back of neck.
Then, the catheters were primed with a 1:1 solution of heparin (1000IU/ml) and dextrose
(50%) and the ends were plugged with stainless steel pins. The urinary bladder was
catheterized via a suprapubic incision with a bladder cannula. The cannula is then primed
with neomycin and plugged with a stainless steel pin covered in silastic, so the rat can
void normally through the urethra. After recovery from general anesthesia, rats were
returned to individual home cages and were able to move freely in the cage. All of these
catheterized rats were trained to accept handling, the activities in the laboratory and to sit
quietly in a restraining cage for several hours at a time. Experiments were performed at
least seven days after the initial surgery.

3. L-arginine transport assay in endothelial cells: Transport of L-arginine into endothelial
cells was measured by the method of Gazzola et al (1981) with minor modification.
Endothelial cells were split into 12-well plates, When cells were confluent, the regular
medium was removed and the cells washed twice with Krebs-HEPES buffer containing (in
mM): 131NaCl, 5.5KCl, 2.5CaCl2, 1.0 MgCl2, 25.0 NaHCO3, 1.0 Na2HPO4, 5.5 Dglucose, 20.0 HEPES. Then, 0.5ml Krebs-HEPES buffer containing 50M L-arginine
with 2l L- [3H]- arginine (2 Ci) was added to each well. Transport was terminated by
removing the media and rapidly washing the cells three times with ice-cold phosphate
buffer solution (PBS) containing 10mM unlabeled L-arginine. The cells were then lysed
with 0.5% Triton X-100 in 0.5M NaOH, and cell associated radioactivity was measured in
a liquid scintillation counter. The background was determined by incubating the cells in
parallel wells with Krebs-HEPES buffer containing 10mM unlabeled L-arginine and the
fraction of radioactivity associated with these cells was determined and subtracted from
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each data point. The time course of L-arginine transport in the HDMEC is linear up to five
minutes, as shown in Figure 1. Since L-3H-arginine uptake by the endothelial cells
reached a maximum after 5 minutes, in all subsequent experiments, measurement of Larginine transport was performed at 3 minutes incubation time. L-3H-arginine uptake
increased linearly with time up to 5 min in HGECs and 10 min in BAECs and arginine
transport was therefore also measured at 3 minutes incubation time in these cells. We also
routinely conducted parallel studies using L-NMA (2mM) which, in addition to acting as a
NOS inhibitor, is also a selective, competitive inhibitor of arginine for the y+ membrane
transporter (Bogle, et al. 1992). In addition, separate studies were conducted on HDMECs
grown in EGM-MV medium, to determine the effect of NG-L-arginine methyl ester (LNAME 2mM, which is transported by a different arginine transporter, not y+ (Bogle, et al.
1992), ADMA (2.5, 10 and 100 M) and creatinine (10mg/dl) on L-arginine transport.
Arginine transport, expressed as pmol arginine transported/ min/ mg of protein was
calculated as follows: Transport of L-arginine (pmol/min/mg.protein) =  [(Radioactivity
of intracellular L-arginine - background)/ total radioactivity in assay buffer x total Larginine concentration in assay buffer] / protein content per well  / incubation time in
min.

4. NOS activity assay in endothelial cells
1) NOS activity assay in intact living endothelial cells: NOS activity was
determined in all cells by measuring L-[3H]arginine conversion to L-[3H]citrulline
according to the method of Davda et al ( Davda, et al. 1993) with minor modifications.
Endothelial cells were split into 12-well plates, when the cells were confluent, the regular
medium was removed and cells were incubated with 0.5ml Krebs-HEPES buffer
containing (in mM): 131NaCl, 5.5KCl, 2.5CaCl2, 1.0 MgCl2, 25.0 NaHCO3, 1.0
Na2HPO4, 5.5 D-glucose, 20.0 HEPES and 50M L-arginine/2l L-[3H]arginine (2Ci;
31.7 pmol arginine) for 1 hour at 370C. The experiment was terminated by removing the
medium and rapidly washing the cells three times with ice-cold phosphate buffer solution
(PBS) containing 10mM unlabeled L-arginine, then cells were solubilized in 0.5ml 1%
Triton X-100 and 50l aliquots were taken for determination of total uptake of L-
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[3H]arginine in a scintillation counter. A portion of the cell homogenate (0.3ml) was
added to 0.7ml 50% Dowex 50WX8-400 (Na+ form) to remove unconverted L[3H]arginine. These samples were vortex mixed for 3 minutes, centrifuged at 2000g for 2
minutes, and the radioactivity of an aliquot (0.5ml) of the supernatant was measured in a
liquid scintillation counter to give the activity due to L-[3H]citrulline. This method of
separating L-[3H]arginine and L-[3H]citrulline has previously been validated by HPLC
and thin-layer chromatography (Davda, et al. 1993 and Liang, et al. 1994 ). The
background radioactivity was determined by the addition of L-[3H]arginine to the cell
medium, which was immediately removed and the cells solubilized. In order to validate
our techniques, we initially measured NOS activity in the HDMECs in response to several
known stimuli and antagonists, i.e. bradykinin, calcium ionophore (A23187), IL-1 +IFN
+LPS, dexamethasone and L-NMA.
NOS activity, expressed as pmol arginine converted to citrulline/ min/ mg of
protein was calculated as follows: NOS activity (pmol/min/ mg. protein)= [(Radioactivity
of L-citrulline - background) / total radioactivity in assay buffer x total L-arginine
concentration in assay buffer] / protein content per well  / incubation time in minutes.
2) NOS activity assay in fractionated endothelial cells. Confluent endothelial cells
grown in T-75 flasks are washed with ice-cold phosphate buffer salt solutions (PH=7.4)
twice, then 10 ml PBS is added. Cells are scraped, transferred to 15 ml centrifuge tube and
centrifuged at 2000gX 5 minutes. After removal of the supernatant, 500 ul
homogenization buffer containing 1mM EGTA, 1mM EDTA, 320mM Sucrose, 50mM
Tris-Hydrochloride, 1mM Diothiothreitol, 1mM PMSF, 1M pepstatin A, 2mM
Leupeptin and 12mM mecaptoethanol is added and the cells are disrupted by freezethawing three times in liquid nitrogen and 37 0C water bath. NOS activity in the cell lysate
is determined by measuring the conversion rate of 3H-L-arginine to 3H-L-citrulline (Bredt,
et al. 1994) with modifications: 50ul of cell lysate (about 25-50ug protein) are added to
50ul buffer to yield final concentrations of reagents as follows: 1mM NADPH, 1M FAD,
1M FMN, 3M BH4, 0.1M calmodulin, 1M DTTR, 1.25mM CaCl2, and 5M Larginine/3H-L-arginine (1Ci/ml, 37MBq/ml, 63.0Ci/mmol). After incubation at 370C for
60 minutes, the reactions is terminated by the additional of 400l stop buffer containing
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50mM HEPES buffer pH 5.5 with 5mM EDTA. Then 400l 50% Dowex resin is added,
vortex 2 minutes, centrifuge 2000 rpm X 2minutes, and measure the radioactivity of 3H-Lcitrulline by scintillation counting.

5. NOx ( nitrate and nitrite) assay
1) NOx assay in urine: The NOx levels urine samples were measured with Griess
Assay according to Stuehr (Stuehr, et al. 1985) using the nitrate reductase enzyme which
reduced NO3 to NO2. The enzyme was produced by E. coli cultured under anaerobic
conditions and in a nitrate reductase-inducing medium for 14h. The generated NO2 was
detected and quantitated by the Greiss reaction. Briefly, 125ul of samples plus 100ul of
HEPES/ammonium formate (1:1) are mixed with then add 25ul of nitrate reductase,
incubated for 60 minutes at 370C in a shaking water bath. During the incubation all of the
NO3 is reduced to NO2 as shown by complete conversion of NO3 standards following
incubation with the enzyme. After the incubation, samples are centrifuged (2000 rpm X
15 minutes) and 100ul of this supernatant is added to a 1:1 (V/V) mixture of Griess
reagent (1.0% sulfanilamide in 0.1% naphthylethylene diamine) in 96 well plates. Samples
are left for 10-15 minutes at room temperature and the absorbance is determined at a
wavelength of 543 nm spectrophotometrically in an ELISA plate reader. A standard curve
is constructed using known concentrations of sodium nitrite and nitrate over the linear
range of the assay (5-500uM).
2) NOx assay in cell medium: In order to obtain a sufficient amount of NOX for
analysis, we seeded ~2x10 5 cells into T25 flasks. NOX is again determined by the Greiss
reaction as the method used for measuring the urinary NOx concentrations with several
modifications to increase the sensitivity of the assay, as follow: Samples are coincubated
with nitrate reductase and glucose-6-phosphate dehydrogenase in the presence of glucose6-phosphate to eliminate interference by high concentrations of NADPH in the Greiss
reaction (Verdon, et al. 1995). The Greiss reaction was modified to improve sensitivity by
sequential addition of cold sulfanilamide, cold HCl and after 5 min, room temperature N(1-naphtyl)-ethylenediamine. The minimum concentration of NOx can be detected with
this method is 0.5uM (Funai, et al. 1997).

34

6. Cellular protein assay
1) Cellular protein assay with standard Bio-Rad method: The principle of the BioRad protein assay is a dye-binding assay in which a differential color change occurs in
response to various concentrations of protein. The absorbance maximum for an acidic
solution of Coomassie Brilliant Blue-G-250 dye shifts from 465nm to 595nm when
binding to protein occurs (Bradford. 1976). This method is a simple and accurate
procedure for determining concentration of solubilized protein. It involves the addition of
an acidic dye to protein solution and subsequent measurement at 595nm with
spectrophotometer or microplate reader. The procedures include: prepare 5 standard
solutions with bovine serum albumin which is representative of the protein solution to be
tested (the linear range of the assay is from 3.25ug/ml to 125ug/ml); Pipette 160ul of each
standard and sample solution into separate microtiter plate wells; Add 40ul of dye reagent
concentrate (containing dye, phosphoric acid, and methanol, Bio-Rad) to each well and
mix thoroughly; Incubate at room temperature for at least 5 min but less than 1hour and
measure absorbance at 595nm. This is a good and sensitive method for protein assay, but
sodium hydroxide and some detergents can interfere. In the NOS activity assay in
fractionated cells, the cellular protein were measured with this method.
2) Cellular protein assay with Bio-Rad DC protein assay: The Bio-Rad DC
protein assay is a colorimetric assay for protein concentration following detergent
solubilization. The reactions employ Lowry assay (Lowry, et al. 1951) with some
improvements including: the reaction reaches 90%of its maximum color development
within 15 minutes and the color changes not more than 5% in 1 hour or 10% in 2 hours
after the addition of reagents. The procedures for microplate assay briefly include: add
20ul of reagent S (Bio-Rad) to each ml of reagent A (an alkaline copper tartrate solution,
Bio-Rad) to make into reagent A’; prepare 4 dilutions of a protein standard containing
from 0.1 mg/ml to 0.8 mg/ml protein with bovine serum albumin with the same buffer as
the sample; pipette 5ul of standards and samples into a clean, dry microtiter plate; add
25ul of reagent A’ in each well; add 200ul reagent B (a dilute Folin reagent, Bio-Rad) into
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each well; after 15 minutes, absorbance can be reached at 750nm. The absorbances will be
stable for about 1hour.

7. L-arginine analogue, asymmetric dimethyl L-arg (ADMA) and symmetric dimethyl Larg (SDMA) assay with HPLC: For measurement of the plasma concentrations of
endogenous NOS inhibitors ADMA and SDMA. The reverse phase HPLC with AccQ Tag
method (Anderstam, et al. 1997) was used with minor modifications. Blood samples were
kept on ice for exactly 90 min, then centrifuged for 15 min. The plasma was harvested and
precipitated with 3% 5-sulfosalicylic acid in a ratio 1:1 (V/V), for 1hour and then
centrifuged again in 40C for 20 min. Finally, the solutions were filtered and stored at 70oC, as described (Anderstam, et al, 1997). This arbitrary time period was chosen to
standardize the handling of all samples whether they were acquired in our laboratory or at
remote sites (outpatient dialysis unit) and transported to us. Samples were prepared as
described (Anderstam, et al. 1997) but instead of spiking individual samples we
constructed separate standard curves. Standards contained equal concentrations of ADMA
and SDMA in the concentration range from 0.625 to 10.0 M, made up in AccQ fluor
borate buffer in a stock of deproteinized control plasma. Samples and standards (30 l)
were injected onto a Waters AccQ Tag 3.9 X 150mm 4 um, silica-based Nova-Pak C18
reversed-phase column at 37 0C using a Waters column heater and control module.
Fluorescence intensity was measured at 250nm (excitation) and 395nm emission (gain
100) using a Waters 474 scanning fluorescence detector. A flow rate of 1 ml/min was
attained using a Waters 600s controller and 616 pump system using the identical gradient
elution table and buffers described by the reference (Anderstam, et al. 1997) with the
exception that we used double the concentration of Triethylamine in buffer A which
improved peak resolution. Recoveries of spiked synthetic ADMA and SDMA added to
control plasma were ~100%. Concentrations of methyl-arginines were calculated using
Millennium chromatography manager (version 2.10) software for integrations and
calculations based on the established standard curves for each run.
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Study I: Effects of plasma from chronic renal disease patients on Larginine transport and endothelial nitric oxide synthase
activity in cultured human endothelial cells
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SUMMARY
In this study, we investigated the effects of human plasma from 5 healthy controls
and 11 chronic renal disease (CRD) patients with moderate renal insufficiency, on the
transport of L-arginine (substrate of nitric oxide synthase, NOS) and NOS activity, in
human dermal microvascular endothelial cells (HDMEC). The primary diseases in these
patients are variable including diabetic mellitus, chronic glomerulonenephritis, chronic
interstitial nephritis, Wegener’s granuloma and obstructive nephropathy. Plasma
concentrations of NOS inhibitors asymmetric and symmetric dimethyl L-arginine
(ADMA, SDMA), creatinine and BUN, were also measured. After incubating HDMEC
with 20% plasma from normal controls or CRD patients for 6 hours, there was no
difference in L-arginine transport between the groups. The NOS activity (measured by
the conversion rate of H3 L-arginine to H3L-citrulline) was variable in these CRD patients.
Data was divided into 2 subgroups where NOS activity was normal (CRDI; individual
values similar to control group mean) and low (<15.5 pmol/min/mg.protein; CRD II;
individual values significantly lower that control group mean). The effect of CRD plasma
on NOS activity in cultured cells was not related to the primary disease, but was predicted
by plasma ADMA levels since plasma ADMA was elevated in CRD II vs both control and
CRD I. There was no correlation with SDMA, BUN and creatinine since these are
uniformly elevated in all CRD patient plasma vs control. When a synthetic solution with
high concentrations of ADMA (equivalent to values in CRD II) were incubated with
HDMEC for 6 hours, we also observed direct inhibition of eNOS activity. Thus, high
plasma levels of ADMA in CRD patients is a marker, and is partly responsible, for the
inhibition of eNOS activity in cultured cells. The elevated ADMA in CRD patients causes
eNOS inhibition in vitro and may cause eNOS deficiency hypertension in vivo. Of note,
the high ADMA in some CRD patients is independent of reduced renal clearance,
suggesting an alteration in ADMA synthesis and/or degradation.

Key words: CRD patients, cell culture, plasma, HDMEC, L-arginine transport,
endothelial NOS activity, ADMA
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INTRODUCTION
Hypertension is very common in chronic renal disease (CRD) patients and is an
important risk factor in the accelerated deterioration of renal function to end stage renal
disease (ESRD). The hypertension in these patients is sometimes difficult to control and
the mechanisms of hypertension in CRD are complex and not well understood (1,2),
although nitric oxide (NO) deficiency may play a role in this hypertension (1,3).
NO is derived from the metabolism of the semi-essential amino acid L-arginine
and is a potent vasodilator (4,5). The nitric oxide synthases (NOS), the key enzymes in
NO production, are widely distributed in many species including man, and are found in
many types of cells. So far, three categories of NOS genes have been cloned and
sequenced; neuronal (n) NOS, inducible (i)NOS and endothelial (e)NOS (6,7). The
synthesis of NO by vascular endothelial cells is continual and plays an important role in
the minute-to-minute control of vascular tone, blood pressure (BP) and blood flow (5,6).
Hypertension occurs in mice with knockout of the eNOS gene (8) and hypertension and
other cardiovascular complications have been reported in man with some (but not all)
eNOS gene polymorphisms (9,10,11). Also, there is evidence that regional vascular
endothelial NO production may be defective in some patients with primary and secondary
hypertension (12). It is therefore possible that insufficient NO production from eNOS
plays a role in some forms of hypertension in man.
In the patients with chronic renal disease, the decrease in renal function causes a
series of alterations of metabolism as well as accumulations of waste products and toxins,
which may lead to endothelial dysfunction, reduced endothelial NO production and hence,
hypertension (2). The purpose of the present study is to test the hypothesis that in uremia,
circulating factors impair endothelial NO production. This was accomplished by
assessing the effects of human plasma obtained from CRD patients with moderate renal
function insufficiency on L-arginine transport and NOS activity in cultured human dermal
microvascular endothelial cells.
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METHODS
Materials: Human dermal microvascular endothelial cells (HDMEC) and
endothelium growth medium (EGM-MV) were obtained from Clonetics Corporation (San
Diego, CA). The following supplies and drugs were used: Minimum essential medium
(MEM, Life Technologies, Inc. Grand Island, NY); fetal bovine serum (FBS, Atlanta
Biologicals, Inc, Norcross, GA). [3H]L-arginine ( L-[2,3,4,5-3H] Arginine
monohydrochloride, 63.0 Ci/mmol, Amersham Life Science, Arlington Hights, IL).
Monomethyl-L-arginine (L-NMA,Calbiochem-Novabiochem Corporation La Jolla, CA);
Il-1 and IFN (Collaborative Biochemical Co, Bedford, MA); Dexamethasone (DEX,
American Reagent Laboratories, Inc, Shirley, NY). Bradykinin (Bk, Bachem Bioscience
Inc., King of Prussia, PA); Protein assay reagents (Bio-Rad Laboratories, Hercules, CA);
Dowex 50WX8-400, L-arginine and all other chemicals were obtained from Sigma
Chemical Co. (St. Louis, MO).
Plasma was collected from 11 CRD patients including 4 patients with diabetic
mellitus, 4 patients with chronic glomerulonephritis, 1 patient with chronic interstitial
nephritis, 1 patient with Wegener’s granuloma, 1 patient with obstructive nephropathy and
5 normal healthy controls (Table 1). The renal function in all CRD patients was similar at
~30% of normal GFR as reflected by plasma creatinine and BUN (Table 2). The
demographic and clinical characteristics of the study populations are shown in Table 1 and
2. The plasmas were collected into heparin coated tubes, spun cold, aliquoted and frozen
at –80oC within 20 minutes of collection and were thawed immediately prior to use.
Cell culture: HDMEC (passage 4-7) were maintained in EGM-V media containing
10 pg/ml human recombinant epidermal growth factor, 1g/ml hydrocortisone, 50 g/ml
gentamicin, 50 ng/ml amphotericin-B, 12 g/ml bovine brain extract and 5% fetal bovine
serum at 37oC in a humidified atmosphere of 5% CO2 and 95% air. All cells tested
positive for Factor VIII and acetylated low density lipoprotein (LDL) uptake and negative
for smooth muscle alpha actin, confirming that they are pure endothelial cells. In
preparation for the experiments, cells were first cultured in T-75 flasks and then
subcultured onto 12-well plates. Once the cells became confluent (usually ~ 5 days when
seeded at a density of 7000 / cm2), the culture medium was replaced with MEM

40

containing 20% human plasma (either individual CRD patient plasma or pooled normal
control). Initial time course experiments were done and we found that cells remained
completely viable when incubated for 6h but that some cell detachment occurred at 24h
and longer, when any human plasmas were used. Therefore, in all experiments described
here, cells were incubated for 6h and then studied for arginine transport or NOS activity.
Determination of L-arginine transport: Transport of L-arginine into endothelial
cells was measured by the method of Gazzola et al (13). Briefly, after 6h incubation with
human plasma, the medium was removed and the cells washed twice with Krebs-HEPES
buffer containing (in mM): 131 NaCl, 5.5 KCl, 2.5 CaCl2, 1.0 MgCl2, 25.0 NaHCO3, 1.0
Na2HPO4, 5.5 D-glucose, 20.0 HEPES. Then 0.5ml Krebs-HEPES buffer containing
50M L-arginine with 2l L- [3H]arginine (2 Ci) was added to each well. Transport was
terminated by removing the media and rapidly washing the cells three times with ice-cold
phosphate buffer solution (PBS) containing 10 mM unlabeled L-arginine. The cells were
then lysed with 0.5% Triton X-100 in 0.5M NaOH, and cell associated radioactivity was
measured in a liquid scintillation counter. The background was determined by incubating
the cells in parallel wells with Krebs-HEPES buffer containing 10mM unlabeled Larginine and the fraction of radioactivity associated with these cells was determined and
subtracted from each data point. The time course of L-arginine transport in the HDMEC is
shown in Figure 1. Since L-3H-arginine uptake by the endothelial cells reached a
maximum after 5 minutes, in all subsequent experiments, measurement of L-arginine
transport was performed at 3 minutes incubation time.
Determination of nitric oxide synthase activity in living cells: NOS activity was
determined in all cells by measuring L-[3H]arginine conversion to L-[3H]citrulline
according to the method of Davda et al (14), with minor modifications. Briefly, after 6
hours incubation, the medium was removed and cells were incubated with 0.5 ml KrebsHEPES buffer containing (in mM): 131 NaCl, 5.5 KCl, 2.5 CaCl2, 1.0 MgCl2, 25.0
NaHCO3, 1.0 Na2HPO4, 5.5 D-glucose, 20.0 HEPES and 50 M L-arginine /2l L[3H]arginine (2Ci; 31.7 pmol arginine) for 1 hour at 370C. The experiment was
terminated by removing the medium and rapidly washing the cells three times with icecold phosphate buffer solution (PBS) containing 10 mM unlabeled L-arginine, then cells
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were solubilized in 0.5 ml 1% Triton X-100 and 50 ul aliquots were taken for
determination of total uptake of L-[3H]arginine in a scintillation counter. A portion of the
cell homogenate (0.3ml) was added to 0.7 ml 50% Dowex 50WX8-400 (Na+ form) to
remove unconverted L-[3H]arginine. These samples were mixed for 3 minutes,
centrifuged at 2000g for 2 minutes, and the radioactivity of an aliquot (0.5 ml) of the
supernatant was measured in a liquid scintillation counter to give the activity due to L[3H]citrulline. This method of separating L-[3H]arginine and L-[3H]citrulline has
previously been validated by HPLC and thin-layer chromatography (15,16). The
background radioactivity was determined by the addition of L-[3H]arginine to the cell
medium, which was immediately removed and the cells solubilized. In order to validate
our techniques, we initially measured NOS activity in the HDMECs in response to several
known agonists and antagonists, i.e. bradykinin, calcium ionophore (A23187), IL-1
+IFN +LPS, dexamethasone and L-NMA.
Determination of plasma concentration of ADMA and SDMA: L-arginine
analogues, asymmetric dimethyl L-arg (ADMA) and symmetric dimethyl L-arg (SDMA)
were measured using reverse phase HPLC with AccQ Tag method (17) with minor
modifications (details in General Method). Briefly, plasma was harvested and precipitated
with 3% 5-sulfosalicylic acid , centrifuged then filtered and stored at -70oC until assay.
Samples and standards (30 l) were injected onto a Waters AccQ Tag 3.9X 150mm 4 um,
silica-based Nova-Pak C18 reversed-phase column at 37 0C using a Waters column heater
and control module. Fluorescence intensity was measured at 250nm (excitation) and
395nm emission (gain 100) using a Waters 474 scanning fluorescence detector.
Concentrations of methyl-arginines were calculated using Millennium chromatography
manager (version 2.10) software for intergrations and calculations based on the
established standard curves for each run.
Measurement of cell protein: The total cellular protein was determined by the BioRad detergent method which uses a modification of the Lowry assay (18) with bovine
serum albumin as a standard.
Calculations and Data analysis: Arginine transport, expressed as pmol arginine
transported/ min/ mg of protein was calculated as follows:
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Transport of L-arginine (pmol/min/mg.protein) =
 [(Radioactivity of intracellular L-arginine - background) / total radioactivity in
assay buffer x total L-arginine concentration in assay buffer] / protein content per well  /
incubation time in min
NOS activity, expressed as pmol arginine converted to citrulline/ min/ mg of
protein was calculated as follows:
NOS activity (pmol/min/ mg. protein)=
 [(Radioactivity of L-citrulline - background) / total radioactivity in assay buffer x
total L-arginine concentration in assay buffer] / protein content per well  / incubation
time in min
Each individual assay was run in triplicate and experiments were repeated at least
three times. Individual number / group are given in the Table or Figure legends. Results
are expressed as mean  SEM. Statistical analysis was performed with the use of Student’s
unpaired t-test and one way ANOVA. Values of p<0.05 are considered to be significantly
different.
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RESULTS
As shown in Table 1, the CRD and control populations were age matched and
CRD patients had significant systolic hypertension (Table 2) despite the fact that all CRD
patients were on one or more antihypertensive medications (Table 1). Figure 1 shows the
time course of L-arginine transport into endothelial cells and it is evident that L-arginine
uptake is linear up to 5 minutes. Based on this preliminary finding, we used a 3 minutes
incubation time for all the L-arginine transport experiments. There was no difference in
L-arginine transport into HDMEC after 6 hours incubation between the mean value for
CRD patient plasma (190  19 pmol/ min/mg.protein) or any individual CRD plasma
value compared to control (198  24 pmol/min/mg.protein).
For the study on NOS activity, we initially found that L-NMA is an effective NOS
inhibitor and at 5 mM inhibits 93-96 % of basal eNOS activity, as shown in Figure 2. Both
the calcium ionophore A23187 (0.5 M for 1h) and bradykinin (1M for 10 min)
significantly increased eNOS activity compared to control (both p<0.01), and 5 mM LNMA inhibited the stimulated eNOS activity by 80-90 % (Figure 2). The effect of control
and CRD patient plasma on NOS activity in HDMEC, is shown in Figure 3. In 11 CRD
patients, plasma from 5 patients significantly inhibited NOS activity compared to control,
and plasma from other 6 patients did not. In the first panel of Figure 4, there was no
difference in the average values of NOS activity between controls and the entire CRD
group, although the variation was greater in the latter. However, when we compared the
effect of each individual CRD patient plasma on NOS activity vs control, the plasma from
6 patients did not affect NOS activity (CRD I) compared to control while plasma from 5
CRD patients significantly inhibited NOS activity (CRD II). As also shown in Figure 4,
as with NOS activity, there was no significant difference between the average plasma level
of ADMA in all CRD patients and in controls. However, when the CRD plasma was
separated into two subgroups depending on the NOS activity, plasma ADMA was high in
the low NOS activity group (CRD II), vs both controls and the group of CRD plasma with
normal NOS activity (CRD I). In the 4th and 5th panels of Figure 4, it is shown that plasma
levels of creatinine and BUN are significantly elevated vs controls in all CRD patients and
that the difference in plasma levels of ADMA between the two CRD plasma subgroups is
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not related to the level of loss of renal function. As shown in the 3rd panel of Figure 4,
unlike ADMA, there is no difference in plasma levels of SDMA between the low and
normal NOS activity CRD subgroups.
The direct effect of ADMA on NOS activity was shown in Figure 5. When
HDMEC were incubated for 6 h with synthetic solutions containing different
concentrations of ADMA, we found that the NOS activity was significantly inhibited by
2.5 M ADMA with further inhibition evident when the concentration of ADMA was
increased to 10 M. However 1M ADMA does not affect the NOS activity. This
concentration is equivalent to the plasma concentration of ADMA in CRD patients with
low NOS activity after 1:5 dilution with cell medium (we used 20% plasma).
To determine whether the differences in NOS activity of CRD patient plasma may
be related to stimulation of iNOS in some cases, we pre-treated some HDMECs with
dexamethasone to inhibit iNOS transcription (19, 20). As shown in Figure 6, although
dexamethasone pretreatment has no effect on NOS activity of control plasma, it does
inhibit the iNOS stimulated by incubation for 24h with a combination of LPS (10g/ml),
IL-1(100 U/ml) and IFN (100U/ml), without affecting the constitutive eNOS activity,
and L-NMA inhibits all NOS activity (Figure 6).

45

DISCUSSION
The prevalence of hypertension in chronic renal disease (CRD) ranges from 60%
to 100% depending on the target populations, cause of renal disease and level of residual
renal function (21). In CRD patients with residual renal function of 30-50% of normal,
the morbidity rate of hypertension is about 65% (22). The pathogenic mechanisms of
hypertension in these patients are likely to be complex and many factors have been
implicated including stimulation of the renin-angiotension aldosterone system; increased
sympathetic activity; endogenous digitalis-like factor and decreased production of
prostaglandins/bradykinin (23,24,25). It is now accepted that NO derived from vascular
endothelial cells plays an important role in maintaining blood pressure and vascular tone
(4,12), and changes in endothelial NO production may also be involved in the
hypertension in CRD. For example, total NO production (measured from 24h urinary
NOX excretions) is reduced in man with CRD of varying causes (26) and in rats with 5/6th
reduction of renal mass (27). Since the substrate for NOS (L-arginine) is synthesized in
the kidney (28,29) a progressive loss of functional renal mass might compromise
endogenous arginine availability. Indeed, chronic L-arginine supplementation is
beneficial in a range of CRD models (28,30,31). Also, there is evidence that circulating
levels of endogenous NOS inhibitors (methylated arginines) increase in renal failure (3),
perhaps secondary to loss of renal clearance. The clinical observations have, of necessity,
been indirect, and in the present study we therefore set out to determine whether factor(s)
in uremic plasma could have a direct impact on endothelial cell NO generation.
We investigated the effect of plasma from CRD patients (vs plasma from normal
kidney subjects) on substrate (L-arginine) transport and NOS activity in cultured human
endothelial cells. There was no effect of any CRD plasma on L-arginine transport after 6
hours incubation with human dermal microvascular endothelial cells. However, the NOS
activity was inhibited by the plasma from ~ 50% of CRD patients. Although we have only
a small group so far (n=11), there was no obvious relationship between the NOS activity of
the plasma and the primary diseases. For example, 2 patients with diabetic nephropathy
showed low plasma eNOS activity while 2 others had normal activity (Table 3). Several of
the patients had immune-mediated diseases (e.g. glomerulonephritis, IgA nephropathy) and
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increased intrarenal NO generation via iNOS, has been reported during the acute phase of
immunologically mediated glomerular diseases (32-35). However, our observations suggest
that there is no iNOS activating activity in plasma from our patients with established,
immune-mediated CRD (or any other primary disease). Pre-treatment of cultured cells with
dexamethasone, which inhibits iNOS transcription (19,20), had no effect on NOS activity
after incubation with CRD patient plasma for 6 hours, thus we are confident that we are
measuring eNOS activity.
All CRD patients in this study were on one or more antihypertensive drugs at the
time plasma was drawn and we considered the possibility that the medications might
influence eNOS activity and perhaps account for the variability in CRD patients plasma
eNOS activity. There was no obvious association between any given drug, or drugs, and the
eNOS activity of plasma (Table 1). The drugs used included diuretics (furosemide and
HCTZ), calcium-channel blockers (amilodipine and diltiazem), -receptor blocker
(metoprolol) and angiotensin II converting enzyme inhibitors (enalapril, captopril and
lisinopril). Studies by others have shown that these drugs either have no effect on NO
production, in the case of -receptor blockers (36) or may increase NO production
(diuretics, calcium channel blockers and angiotensin II converting enzyme inhibitors) in
vascular endothelial cells (37, 38). Therefore, the inhibition of eNOS activity by CRD
patients plasma is likely to be directly related to some common feature of the chronic renal
disease.
To determine why the plasma from some CRD patients had low NOS activity, we
measured the concentrations of the L-arginine analogues, ADMA and SDMA. It has been
reported that some methylated arginines can competitively bind NOS and inhibit NOS
activity (3). Although we found that the average plasma level of ADMA in all 11 CRD
patients is not different to the normal control, we did find differences when we separated the
CRD patients in subgroups according to the level of NOS activity of their plasma. All
patients with low NOS activity had high plasma concentrations of ADMA, whereas those
whose plasma NOS activity was normal, had normal levels of ADMA. A “cause and effect”
relationship is likely since we found that synthetic medium containing 2.5 M ADMA
(equivalent to the plasma concentration seen in the CRD II subgroup) can inhibit NOS
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activity in the endothelial cells after 6 hours incubation. It is important to point out
however, that plasma from the CRD II subgroup, which lowers eNOS activity, is diluted 1:5
so that the ADMA concentration in contact with the cells is only ~ 0.5uM; a concentration
that we have shown will not influence eNOS activity when added to synthetic solutions.
Thus, it is likely that in vivo, elevated plasma ADMA is a partial cause and is also a marker
for other eNOS lowering agents in the plasma of some patients with CRD.
Why high plasma levels of ADMA occur in some, but not all CRD patients is not
clear. The original explanation in ESRD patients was that ADMA accumulates in plasma
because of loss of renal clearance (3), and we have found that all ESRD patients studied
exhibit high plasma concentrations of ADMA (39). However, in the present study, there
was no correlation between level of residual renal function and the plasma levels of ADMA
and both BUN and creatinine levels were uniformly high in all CRD patients, despite
marked differences in plasma ADMA. Recently, an increase in plasma ADMA levels have
been reported in hypercholesterolemic states in the absence of reduced renal clearance (40).
This suggests that alterations in synthesis and/or catabolism of methylated arginines may
also contribute to functional NOS inhibition in some circumstances, including, perhaps,
CRD. There is evidence that degradation of methylarginines is regulated by the enzyme
dimethylarginine dimethylaminohydrolase (DDAH), which is widely distributed in many
tissues and is present in high concentrations in kidney and aorta of the rat (41). It has been
shown experimentally that inhibition of DDAH (which allows accumulation of ADMA),
inhibits endothelium dependent relaxation (42).
Most likely multiple factors determine whether NO deficiency will occur in a given
patient with CRD. Recently, it was reported that some patients with renal diseases have an
eNOS gene polymorphism which could be related to the renal function deterioration (10).
Studies in animal models of CRD indicate reduced expression of the eNOS enzyme within
the vasculature and kidney (27). The hyperparathyroidism of CRD apparently contributes
to the depression of NOS activity since parathyroidectomy and Ca channel blockade,
reverse these abnormalities in vascular NO (27). Another reason for reduced NOS activity
in CRD relates to increased oxidant stress where oxygen free radicals inactivate newly
formed NO and prevent the normal vasodilatory response (43). Over time, oxidative stress
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leads to non enzymatic glycation and oxidation and the accumulation of advanced
glycosylated end products (AGEs) (44). AGEs modify the vascular wall such as to
“quench” NO and thus reduce the vasodilatory action of NO (and other agonists) (45) and
also downregulate eNOS in cultured vascular endothelial cells (46).
Most likely the development of NO deficiency in CRD depends on many factors.
We speculate that an early rise in the plasma level of ADMA in some CRD patients will
increase the rate of chronic renal disease to the end stage of renal failure and may lead to
increased morbidity due to cardiovascular complications. It is certainly true that chronic
NOS inhibition in animals produces ‘de novo” renal disease (47) and exacerbates underlying
renal disease (48).
In summary, in these cell culture studies we have found that plasma from CRD
patients has a variable effect on eNOS activity, depending on the ADMA concentration. We
suggest that this reflects the “in vivo” situation and that high plasma ADMA early in the
course of CRD may be a bad prognosticator of a rapid rate of progression to ESRD. Why
some CRD patients have high plasma ADMA levels is not clear at this time.
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L-arginine transport in
human dermal microvascular endothelial cells
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Figure1.

Time course of L-arginine transport in HDMEC. Transport was initiated by
addition of 50uM L-arginine/ L-3H-arginine to the cells incubated with
Kreb-HEPES buffer, and specific uptake was determined at indicated times.
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Effects of bradykinin and calcium ionophore (A23187) on the NOS activity
in HDMEC. Cells were incubated with 1M bradykinin and 0.5M A23187
for 1 hour, and NOS activities were detected by measuring the conversion
rate of L-arginine to L-citrulline. L-NMA 5mM was added to some wells to
confirm the specific NOS activity. Results are meanSEM of two separate
experiments, each performed in triplicate. * P<0.01 compare to the control.
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Differential NOS activity in CRD patients
and normal control
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Differential influence of plasma from control and 11 CRD patients on
NOS activity in human dermal microvascular endothelial cells.
Each dot represents the value of NOS activity in individual patients or
control respectively. Group 1: patients with normal NOS activity; Group 2:
patients with low NOS activity.
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Effects of synthetic solutions with different concentrations of ADMA (1M,
2.5M and 10M ) on NOS activity in human dermal microvascular
endothelial cells. Cells were incubated with 20% fetal bovine serum 6 hours
before NOS activity were measured over the following 60 minutes.
*: P<0.05 compared to control.
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Effects of combination of LPS, IL-1 and IFN- on the NOS activities in
HDMEC. After incubation with LPS (10g/ml) only, LPS with IL1(100/ml) and IFN- (100/ml) and pre-treatment with dexamethasone
(10g/ml) 1 hour for 24 hours, NOS activity was detected by the measuring
the conversion rate of L-arginine to L-citrulline. L-NMA 5mM was added to
confirm the specific NOS activity. * P<0.01 compare to control, # P<0.01
compare to the combination of LPS, IL-1 and IFN-.
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Table1: Demographic and clinical characteristics of the study population

CRD

Age

Sex

BSA

1

29

M

1.67

FSGS +sol Kid

CEI

2

51

M

2.22

Wegners

CCB

3

56

M

1.75

CIN

CCB, D

4

32

F

2.30

CGN

CEI

5

62

F

2.59

DM

BB, D

6

63

F

2.60

DM

BB

7

65

M

2.10

GN

CCB.D

8

78

M

1.92

DM

D

9

59

M

1.84

DM

CEI

10

67

M

2.24

IgA+Sol Kid

D

11

67

M

2.11

Obst. Neph

BB

Ave

574

Gender

2.120.09

None

None

(n=11)
Control
Ave (n=5)

Disease

Med*

M8/F3
586

Gender

2.090.10

M4/F1

* CRD patients were on one or more anti-hypertensive agents; D=diuretic,
CCB= calcium channel blocker, CEI=angiotensin converting enzyme inhibitor, BB=betablocker. BSA: body surface area (m2).
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Table 2: Blood pressure, renal function in CRD patients and Controls

Blood pressure (mmHg)
Systolic

Ccr

BUN

PCr

Diastolic

(mg/dl)

(mg/dl)

(ml/min/m2 BSA)

CRD

1488*

803

46.31.1*

4.01.5*

335*

Control

1176

724

10.03.1

0.80.2

11922*

* different vs control. BUN: blood urea nitrogen; Pcr: plasma concentration of creatinine;
Ccr: plasma creatinine clearance.
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Study II: Effects of plasma from patients with end stage renal disease on substrate
transport and nitric oxide synthase activity in endothelial cells.
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SUMMARY
Nitric oxide (NO), a potent vasodilator synthesized by endothelial cells, plays an
integral role in control of vascular tone, blood pressure, and blood flow. Hypertension in
end-stage renal disease (ESRD) may also involve lack of endothelial NO, as suggested by
reduced total NO synthesis in dialysis patients. To test this hypothesis, uremic plasma was
obtained from dialysis patients and its effect was tested on arginine transport and NO
synthase (NOS) activity in cultured vascular endothelial cells. Both endothelial (e)NOS
activity (p<0.05) and L-arginine transport (p<0.01) were reduced in human dermal
microvascular endothelial cells (HDMEC) incubated for six hours with 20% uremic plasma
from peritoneal dialysis (PD) and hemodialysis (HD) patients obtained immediately predialysis. Hemodialysis did not remove the eNOS inhibitory activity and only partially
reversed inhibition of L-arginine transport. Dexamethasone pre-treated cells demonstrated
that immediately post-hemodialysis blood did not cause any activation of inducible NOS
(iNOS) under these study conditions. NO production (as measured by the stable oxidation
products NO2+NO3=NOx) was lower in HDMECs incubated with uremic vs control
plasma and addition of exogenous arginine increased NO production by cells previously
exposed to uremic medium. These cellular findings complement our recent clinical studies
and suggest that low eNOS activity may contribute to hypertension in ESRD patients.

Key words: End stage renal disease, plasma, endothelial cells, L-arginine transport,
NOS activity, ADMA and SDMA, Nitrate and nitrite
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INTRODUCTION
Nitric oxide (NO) is derived from the metabolism of the semi-essential amino
acid L-arginine and is a potent vasodilator (1,2). The nitric oxide synthases (NOS), the
key enzymes in NO production are widely distributed in many animals including man.
So far, three categories of NOS genes have been cloned and sequenced; neuronal
(n)NOS, inducible (i)NOS and endothelial (e)NOS (2,3). The synthesis of NO by
endothelial cells is continual and plays an important role in the minute-to-minute control
of vascular tone, blood pressure (BP) and blood flow (1,4). Hypertension occurs in mice
with knockout of the eNOS gene (5) and hypertension and other cardiovascular
complications have been reported in man with certain eNOS gene polymorphisms (6).
Also, there is evidence that regional vascular endothelial NO production may be
defective in some patients with primary and secondary hypertension (7). It is therefore
possible that insufficient NO production from eNOS plays a role in some forms of
hypertension in man.
Hypertension is a major complication of end stage renal disease (ESRD) and
negatively affects long-term survival (8,9,10). Hypertension in ESRD patients is, in part,
caused by volume overload, but may involve NO deficiency as well. Indeed, we have
reported reductions in total NO synthesis (from 24h urinary NO2 + NO3 = NOX
production) in both peritoneal dialysis (PD) and hemodialysis (HD) patients (11, 12).
Patients with ESRD lack functional renal mass and since the substrate for NO production,
L-arginine, is synthesized in the normal kidney (13), NOS substrate deficiency may occur
in ESRD. In addition, accumulation of endogenously produced circulating compounds
that accumulate in renal failure may competitively inhibit the L-arginine: NO pathway
(14).
The purpose of the present study is to assess the effects of uremic plasma obtained
from PD and HD patients on the L-arginine transport and NOS activity in cultured
vascular endothelial cells. The majority of the studies were conducted on human dermal
microvascular endothelium but some experiments were also done on human glomerular
endothelial cells and bovine thoracic aortic endothelium.
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METHODS
Materials: Human dermal microvascular endothelial cells (HDMEC) and
endothelium growth medium (EGM-MV) were obtained from Clonetics Corporation (San
Diego, CA). Human glomerular endothelial cells (HGEC) and CS-C growth medium were
obtained from Cell System Corp. (Kirkland, WA). The bovine aortic endothelial cells
(BAEC) were established by us in primary culture from thoracic aortas harvested from the
local abattoir. The following supplies and drugs were used: Minimum essential medium
(MEM, Life Technologies, Inc. Grand Island, NY); fetal bovine serum (FBS, Atlanta
Biologicals, Inc, Norcross, GA). [3H]L-arginine ( L-[2,3,4,5-3H] Arginine
monohydrochloride, 63.0Ci/mmol, Amersham Life Science, Arlington Hights, IL).
Monomethyl-L-arginine (L-NMA,Calbiochem-Novabiochem Corporation La Jolla, CA);
Dexamethasone (DEX, American Reagent Laboratories, Inc, Shirley, NY). Protein assay
reagents (Bio-Rad Laboratories, Hercules, CA); Dowex 50WX8-400, L-arginine and all
other chemical reagents were obtained from Sigma Chemical Co. (St. Louis, MO).
Subject: The human plasma was from PD and HD patients, the latter including
pre- and immediately post-hemodialysis (pre-HD and post-HD), and from normal healthy
controls. The clinical characteristics of the study populations are shown in Table 1.
These parameters showed that all of these patients were receiving adequate dialysis
treatment. The HD and control plasmas were harvested in groups and were pooled (from
batches of 2 individuals) and frozen at -80oC. The PD plasmas were not collected in
groups and were frozen as individuals and pooled (2-3 Individuals) immediately prior to
use. All blood samples were collected into heparin coated tubes, spun cold, aliquoted and
frozen within 20 minutes of collection and were thawed immediately prior to use. The
dialysate for PD is Dineal PD solution (Baxter, Deerfield IL) and for HD is bicarbonate
dialysis solution. All HD patients were dialyzed with polysulfone membranes on F-80
dialyzers (Fresenius USA: Lexington, MA).
Cell culture: HDMEC (passage 4-7) were maintained in EGM-V media containing
10 pg/ml human recombinant epidermal growth factor, 1g/ml hydrocortisone, 50g/ml
gentamicin, 50ng/ml amphotericin-B, 12g/ml bovine brain extract and 5% fetal bovine
serum. HGECs (passage 4-7) were maintained in CS-C medium and BAECs (passage 24) were maintained in DMEM + 10% FBS. All cells were incubated at 37oC in a
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humidified atmosphere of 5% CO2 and 95% air and had tested positive for Factor VIII and
acetylated low density lipoprotein (LDL) uptake and negative for smooth muscle alpha
actin, confirming that they are pure endothelial cells. In preparation for the experiments,
cells were subcultured onto 12-well plates and once they became confluent (usually ~5
days for HDMECs when seeded at a density of 7000/ cm2; ~7 days at a density of
5000/cm2 for HGEC and ~3 days at a density of 15,000/cm2 for BAECs), the culture
medium was replaced with MEM containing 20% human plasma (uremic plasma or
normal control ). Initial time course experiments were done and we found that cells
remained completely viable when incubated for 6 hours but that some cell detachment
occurred at 24h and longer, when any of the human plasmas were used. Therefore, in all
experiments described here, cells were incubated for 6h and then studied for arginine
transport or NOS activity.
Determination of L-arginine transport: Transport of L-arginine into endothelial
cells was measured by the method of Gazzola et al (15) with modifications (see details in
General Method and Study I). Briefly, after 6h incubation with human plasma, the
medium was removed and the cells washed twice with Krebs-HEPES buffer. Then 0.5ml
Krebs-HEPES buffer containing 50M L-arginine with 2l L- [3H]arginine (2 Ci) was
added to each well. Transport was terminated by removing the media and rapidly
washing the cells three times with ice-cold phosphate buffer solution (PBS) containing
10mM unlabeled L-arginine. The cells were then lysed with 0.5% Triton X-100 in 0.5M
NaOH, and cell associated radioactivity was measured in a liquid scintillation counter.
The background was determined by incubating the cells in parallel wells with KrebsHEPES buffer containing 10mM unlabeled L-arginine and the fraction of radioactivity
associated with these cells was determined and subtracted from each data point.
Determination of nitric oxide synthase activity in living endothelial cells: NOS
activity was determined in all cells by measuring L-[3H]arginine conversion to L[3H]citrulline according to the method of Davda et al (16), with modifications (details in
General Method and study I). Briefly, after 6 hours incubation, the medium was removed
and cells were incubated with 0.5ml Krebs-HEPES buffer containing 50M L-arginine/2l
L-[3H]arginine (2Ci; 31.7 pmol arginine) for 1 hour at 370C. The experiment was
terminated by removing the medium and rapidly washing the cells three times with ice-cold
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phosphate buffer solution (PBS) containing 10mM unlabeled L-arginine, then cells were
solublized in 0.5ml 1% Triton X-100 and 50ul aliquots were taken for determination of total
uptake of L-[3H]arginine in a scintillation counter. A portion of the cell homogenate (0.3ml)
was added to 0.7ml 50% Dowex 50WX8-400 (Na+ form) to remove unconverted L[3H]arginine. These samples were vortex mixed for 3 minutes, centrifuged at 2000g for 2
minutes, and the radioactivity of an aliquot (0.5ml) of the supernatant was measured in a
liquid scintillation counter to give the activity due to L-[3H]citrulline.
In separate experiments we studied the effects of exogenous arginine (both L-,
and D-arginine) on NOS activity in endothelial cells previously incubated with control
and pooled pre- and post-HD human plasma. L-arginine was added to some wells in the
final concentrations of 50M and 200M , and D-arginine in a concentration of 50M.
After 6 hours incubation, the medium was removed and NOS activity was measured over
the next hour.
Determination of nitric oxide synthase activity in fractionated endothelial cells:
The NOS activity in fractionated cells was measured according to reference (17) with
minor modifications (details in General Method). After 6 hours incubation with the human
plasma from normal control, PD and HD (pre and post) patients, confluent endothelial
cells grown in T-75 flasks were washed twice with ice-cold phosphate buffer salt solutions
(PH=7.4). Then we added 10 ml PBS to the flasks, scraped the cells and transferred to 15
ml centrifuge tube and centrifuged 2000g X 5 minutes, removed the supernatant and
added 500 ul homogenization buffer containing 1mM EGTA, 1mM EDTA, 320mM
Sucrose, 50mM Tris-Hydrochloride, 1mM Diothiothreitol, 1mM PMSF, 1uM pepstatin A,
2mM Leupepton and 12mM mecaptoethanol. The cells were disrupted by freeze-thawing
three times in liquid nitrogen and 37 0C water bath. NOS activity in the cell lysate was
determined by measuring the conversion rate of 3H-L-arginine to 3H-L-citrulline in the
condition of enough cofactors including NADPH, calmodulin, BH4, FAD and FMN.
Measurement of NO production from NOX level: We measured NO production
from NOX level in the media of HDMECs to assess the impact of excess L-arginine on
the ability of the uremic factors to lower eNOS activity. In
order to obtain a sufficient amount of NOX for analysis we seeded ~2 x 10 5 cells into
T25 flasks. These were grown to confluence and then incubated for 6 h with normal
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plasma and uremic plasma, with and without 100 M L-arginine or 100M D-arginine.
The cells were then incubated with 1ml MEM for 2 h during which they were rocked (to
ensure that this low volume of medium always covered the cells), then the medium was
harvested and NOX was determined by the Greiss reaction as previously reported by us
(18) with several modifications to increase the sensitivity of the assay, as follow: Samples
were coincubated with nitrate reductase (NAD(P)H) and glucose-6-phosphate
dehydrogenase in the presence of glucose-6-phosphate to eliminate interference by high
concentrations of NADPH in the Greiss reaction (19). The Greiss reaction was modified
to improve sensitivity by sequential addition of cold sulfanilimide, cold HCl and after 5
min, room temperature N-(1-naphtyl)-ethylenediamine (20).
Determination of plasma concentration of ADMA and SDMA: L-arginine
analogues, asymmetric dimethyl L-arg (ADMA) and symmetric dimethyl L-arg (SDMA)
were measured using reverse phase HPLC with AccQ Tag method (21) with minor
modifications (details in General Method). Briefly, blood samples were collected on ice
then centrifuged, the plasma was harvested and precipitated with 3% 5-sulfosalicylic acid
and then centrifuged again. Finally, the solutions were filtered and stored at -70oC.
Samples and standards (30 l) were injected onto a Waters AccQ Tag 3.9X 150mm 4 um,
silica-based Nova-Pak C18 reversed-phase column at 37 0C using a Waters column heater
and control module. Fluorescence intensity was measured at 250nm (excitation) and
395nm emission (gain 100) using a Waters 474 scanning fluorescence detector.
Concentrations of methyl-arginines were calculated using Millennium chromatography
manager (version 2.10) software for integrations and calculations based on the
established standard curves for each run.
Measurement of cell protein: The total cellular protein was determined by the
Bio-Rad detergent method which uses a modification of the Lowry assay (22) with
bovine serum albumin as a standard.
Experiments were repeated at least three times. Individual numbers are given in
the Table or Figure legends. Results are expressed as mean  SEM. Statistical analysis
was performed with the use of Student’s unpaired t-test and one way ANOVA. Values of
p<0.05 are considered to be significantly different.
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RESULTS
The effect of uremic plasma on L-arginine transport into HDMECs is shown in
Figure 1. After 6 hours incubation with 20% uremic plasma, the L-3H-arginine uptake
was significantly inhibited by both the PD and pre-HD plasma compared to control
(P<0.01), and there was no difference between the PD and HD treatment groups.
Hemodialysis did remove some of the arginine transport inhibitory effect of uremic
plasma, since in the post-HD plasma the inhibition of L-arginine uptake was attenuated
relative to pre-HD (P<0.05), but remained below control (P<0.05).
As shown in Figure 1, 80%~ 90% of arginine transport is inhibited by L-NMA in
cells incubated in control and uremic plasma, indicating that in these cultured cells the
cationic amino acid y+ transporter is the main method of intracellular arginine transport.
In comparison to L-NMA, L-NAME was completely ineffective in reducing L-arginine
transport in HDMECs (Figure 2), which was anticipated since L-NAME uses a neutral
amino acid transporter rather than the y+ (23). Asymmetric dimethylarginine (ADMA)
did exert some
inhibitory effects on L-arginine transport at a concentration of 100 M but not at lower
concentrations of 2.5 M or 10 M, which include the uremic range, see below.
Furthermore, uremic level of creatinine (10mg/dL) has no effect on L-arginine transport
in these cells.
The effects of plasma from ESRD patients on NOS activity in HDMECs were
shown in Figure 3. After 6 hours incubation with 20% uremic plasma obtained from both
PD and pre-HD patients, NOS activity was significantly, and similarly inhibited
compared to control (P<0.05) by ~25-30%. There was no difference between the NOS
inhibitory effect of pre - vs post - HD plasma (Figure 4). Since HD may activate iNOS
(24) which could influence the NOS activity of post-HD plasma, we also conducted
parallel studies in cells pretreated with dexamethasone (10ug/ml) for 1h, to suppress
iNOS synthesis (25). As shown in Figure 4: there was no dexamethasone - inhibitable
NOS activity in control, pre- or post HD suggesting that we are measuring eNOS activity
in all studies.
To determine if the inhibition of eNOS activity is related to insufficient cofactors
rather than inhibition of intrinsic eNOS activity, we measured NOS activity in fractionated
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endothelial cells in the presence of enough cofactors (see methods) including NADPH,
FMN, FAD, BH4 and calmodulin. As shown in Figure 5, the inhibition of NOS activity by
plasma from PD, pre- and post-HD patients persisted in the fractionated endothelial cells,
suggesting that co-factor deficiency was not the cause.
Although the majority of studies were conducted in HDMECs, we also showed
that both NOS activity and L-arginine transport in HGECs and BAECs were similarly
inhibited by plasma from PD and HD patients vs controls (Table 2).
In an attempt to determine the mechanisms of NOS inhibition by the plasma from
these patients, we measured the concentrations of ADMA and SDMA in these uremic
plasmas. We found that plasma concentration of both ADMA and SDMA were increased
in PD and HD (pre- and post-) compared to controls. Plasma levels of the NOS inhibitor
ADMA were elevated 5 times the control value in PD patients and 10 times in HD
patients (Table 3).
In a final series of experiments we investigated whether excess exogenous Larginine and D-arginine in the incubation medium could prevent the “NOS inhibitory"
activity of ESRD plasma on HDMECs. Excess L-arginine apparently lowered NOS
activity in cells incubated with control plasma (from 17.5  0.6 pmols/min/mg protein
with 50 M L-arginine, to 15.4  0.6 pmols /min/mg protein with 100 M L-arginine,
p<0.05). In fact, this reduction in NOS activity is probably artifactual because the excess
"cold" L-arginine that entered the cell during the 6h incubations, competes with the 3H-Larginine used to measure NOS activity. In contrast, excess L-arginine had no apparent
effect on NOS activity in cells incubated with uremic plasma (13.3  0.4 pmols /min/mg
protein with 50 M L-arg vs 14.1  0.3 pmols /min/mg protein with 100 M L-arginine).
This presumably reflects a true increase in NOS activity which is masked by competition
between excess L-arginine and endogenous NOS inhibitors in uremic plasma. However,
in order to examine this question more directly we also measured NOX production. As
shown in Figure 6, NOx production from cells incubated in uremic plasma is significant
lower than in the healthy control plasma. After the addition of exogenous L-arginine, the
production of NOx from the cells incubated with uremic plasma increases and is no
longer different compared to the control. The addition of D-arginine has no effect on the
NOx production.
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DISCUSSION
The majority of patients with ESRD are hypertensive irrespective of their primary
renal disease (8,9,10,26,27,28). Volume overload contributes greatly to hypertension,
although in many patients, uncontrolled hypertension occurs independent of volume
status. NO deficiency has been suggested to contribute as a volume-independent cause of
hypertension in ESRD (13). We have recently conducted carefully controlled clinical
studies in ESRD patients on both PD and HD and have reported a reduction in total NO
production compared to subjects with normal renal function (11,12). Our assumption in
this clinical study was that diminished total NO production reflected, at least in part, a
reduction in "vasoactive NO" produced by vascular endothelial cell eNOS. The present
study was designed to directly test this possibility and for the first time, we provide
evidence which implicates uremia as a cause of eNOS inhibition. We found that factor(s)
in plasma from both PD and HD patients reduced NOS activity in cultured vascular
endothelial cells by ~30% compared to control. Since these cultured cells are only
exposed to 20% plasma for 6h, it seems likely that in vivo, the eNOS-inhibitory actions
of uremic plasma are even more pronounced. We observed a NOS inhibitory action of
uremic plasma in both dermal microvascular and glomerular capillary endothelial cells of
human origin, as well as in bovine endothelial cells from the aorta. This suggests that the
NOS inhibitory effect of uremic plasma will be widespread throughout the circulation,
which in turn implicates NO deficiency from eNOS as a cause of increased peripheral
resistance and thus elevated blood pressure in ESRD.
Having described the phenomenon, we also investigated the cellular mechanism
by which uremic factor(s) in ESRD plasma inhibits eNOS. Our original hypothesis,
which prompted our earlier clinical studies, was that ESRD represents a state of arginine
(i.e. substrate) deficiency. This was based on the fact that arginine utilized by eNOS is
derived both from the diet and from that made endogenously, mainly by the kidney
(13,29). In ESRD a lack of functional renal mass compromises this latter source of
arginine generation which could lead to arginine deficiency and impaired NOS. We and
others have reported low-normal to mildly subnormal plasma arginine values in ESRD
patients (11,12,13). However, the plasma arginine levels in ESRD always remain well
above the Km of the eNOS enzyme (30) which should not, therefore, lead to substrate-
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dependent falls in NO production. These apparently discrepant observations could be
reconciled if uremic factors inhibit arginine transport into the endothelial cell, thereby
creating low, rate-limiting intracellular arginine levels. For this reason we investigated
the effect of uremia on arginine transport and determined that indeed, uremia does inhibit
arginine entry into endothelial cells. The majority of endothelial cell arginine uptake is
via the L-NMA inhibitable y+ transporter (23), and transport via the y+ transporter is
decreased by ESRD plasma. Considering that both renal production of arginine and
arginine transport into endothelial cells are reduced in ESRD, we speculate that the
normal to mildly sub-normal values of plasma arginine encountered in ESRD do indeed
reflect relative arginine deficiency. This view is supported by the observation that orotic
acid levels (a marker for arginine deficiency) are increased in uremia (31).
Since plasma from ESRD patients lowers arginine transport and also, acutely
(within 6h) inhibits eNOS activity, there must be NOS inhibitory factors present in
uremic plasma. There are a number of endogenous arginine analogues that can inhibit
NOS when present in sufficient quantities and there is evidence that these accumulate in
ESRD. For example, plasma concentrations of asymmetric dimethylarginine (ADMA)
increase in renal failure patients, possibly in concentrations that inhibit NO synthesis
(14), although this is controversial (14,21,32,33). In our studies we have found increases
in plasma ADMA in both PD and HD patient plasma, in a concentration range where
NOS activity would be affected. It is likely that the NOS inhibitory activity of uremic
plasma is due to arginine analogs, since we were able to reverse the inhibition of NO
production (measured by NOX levels) with excess unlabelled arginine in the cell
incubation medium. This has important therapeutic implications since this observation
provides a mechanism for the protective effect of chronic arginine supplementation as a
method of lowering BP and preserving renal function in renal disease (34, 35).
It has been reported that some types of human endothelial cells can express both
the constitutive eNOS and the iNOS when appropriately stimulated (36). Hemodialysis
provokes the release of cytokines which are iNOS stimulators (37) and we were
concerned that some of the remaining NOS activity seen in endothelial cells incubated
with HD patient plasma, might reflect iNOS activity. However, pre-treatment of vascular
endothelial cells with glucocorticoids such as dexamethasone prevents synthesis of iNOS
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and thus prevents cytokine-stimulated increases in iNOS activity (25,38). Since
dexamethasone pre-treatment had no effect on NOS activity in cells incubated with
normal control, pre- or post HD patient plasma in our study, we conclude that in these
studies only eNOS activity is operating in the cultured endothelial cells. Of importance,
this also shows that post-HD plasma contains an equal eNOS inhibitory activity to preHD plasma, suggesting that NOS inhibitory activity in ESRD plasma is not removed by
regular HD. Another study also reported that after HD, there is a little decrease of
ADMA and SDMA in the plasma of ESRD patients, but still significantly higher than the
control. The high plasma levels of ADMA and SDMA may be responsible for the
inhibition of NOS activity (39). However, recently, Hand et, al. reported that regular HD
can correct the impaired venodilation in response to acetylcholine in ESRD and suggest
that dialysis could remove the eNOS inhibitors which accumulated in the ESRD (40).
These differences may be related to the different dialysis facilities and patient’s
conditions. The exact effects of HD on eNOS activity need to be further studied.
ESRD patients are on many different medications which could potentially have an
impact on eNOS activity. The antihypertensive agents used are listed in Table 1 and
include diuretics (furosemide and HCTZ), -receptor blocker (metoprolol) and angiotensin
II converting enzyme inhibitors (enalapril, captopril and lisinopril). There is evidence that
these drugs are either not related to NO production (-receptor blocker) (41) or increase
NO production (diuretics and angiotensin II converting enzyme inhibitors) (42, 43) in
vascular endothelial cells. Therefore, the inhibition of eNOS activity by CRD patients
plasma is presumably directly related to the chronic renal disease.
In conclusion, intracellular NOS activity, extracellular to intracellular L-arginine
transport and NOx production were all significantly reduced in HDMECs incubated with
uremic plasma. These cell culture studies complement clinical studies that implicate a
role for a low NO state in hypertensive ESRD patients.
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Figure 1.

#
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Pre-HD

PD

Post-HD

Effects of peritoneal dialysis and hemodialysis on the L-arginine
transport in HDMEC. After 6 hours incubation with the cells, the Larginine uptake was determined by the addition of 50uM L-arginine/L-3Harginine to the cells incubated with Kreb-HEPES buffer in 3minutes. LNMA 5mM was added to some wells to confirm the specific L-arginine
transport. Results are mean SEM of three separate experiments, each
performed in triplicate. * P<0.01 compared to control, # P<0.05 compare
to pre-HD and control. Pre-HD: pre-hemodialysis, post-HD: posthemodialysis.
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Figure 2.

Control L-NAME L-NMA ADMA ADMA ADMA Creatinine
2mM 2mM 2.5M 10M 100M 10mg/dL

Effects of different L-arginine analogs and uremic level of creatinine
on L-arginine transport in HDMEC. *: P<0.01 compared to control.
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Figure 3.
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Effects of human plasma (including normal control, PD and pre-HD
patients) on the NOS activity in HDMEC. After 6 hours incubation with the
cells, NOS activity was determined by measuring the conversion rate of Larginine to L-citrulline. L-NMA 5mM was added in some wells to confirm
the specific NOS activity. Results are mean SEM of three separate
experiments, each performed in triplicate. * P<0.05 compared to control,
PD: peritoneal dialysis, pre-HD: pre-hemodialysis.
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Comparison of the differences of NOS activities in pre- and posthemodialysis with and without dexamethasone in HDMEC. After pretreatment with dexamethasone (10ug/ml) 1 hour, the cells were incubated
with human plasma (including normal control, pre- and post-hemodialysis
patients) in 6 hours, NOS activity was detected by measuring the
conversion rate of L-arginine to L-citrulline. Results are mean SEM of
three separate experiments, each performed in triplicate. * P<0.05
compared to the control.
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Figure 5:

*
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Effects of plasma from normal control, peritoneal dialysis (PD) patients and
hemodialysis (HD) patients on NOS activity in fractionated human dermal
microvascular endothelial cells (HDMEC). NOS activity was detected by
measuring the conversion rate of L-arginine to L-citrulline after 5M Larginine/3H-L-arginine were added in the homogenized cell solutions with
FAD, FMN, NADPH, BH4 and calmodulin. * : P<0.05 compared to
control.
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Figure 6:
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Effects of plasma from normal control and uremic plasma on NOx (nitrate
and nitrite ) production on human dermal microvascular endothelial cells
(HDMEC). After 6 hours incubation with normal control plasma and
uremic plasma with and without 100M L-arginine and D-arginine, the
cells were incubated with MEM medium for 2 hours incubation. The NOx
concentration was then measured in the cell medium. *: P<0.05 compare
to baseline of the control.
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Table 1:The clinical characteristics of the patients with end stage renal disease and normal
control.

Blood pressure(mmHg)
Systolic

Control

KT/V

Diastolic

BUN

PCr

(mg/dl)

(mg/dl)

0.80.2

Medications$

None

1176

724

10.3

1274

745

426*

10.13.2*

BB, CEI, D

1368*

693

748*

10.21.4*

BB,CEI, D

(n=5)
PD
(n=6)
HD
(n=5)

1.50.1

324*#

3.20.4*#

$: Antihypertensive treatment: BB, Beta-blocker; CEI, Angiotension converting enzyme
inhibitor; D, diuretic drugs.
*: P<0.05 vs control. #: after hemodialysis and P<0.05 vs control.
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Table 2: Effects of uremic plasma on NOS activity and L-arginine transport in
HGEC and BAEC.

NOS activity

L-arginine transport

(pmol/min/mg.protein)

Control

HGEC Basic
L-NMA

BAEC Basic
L-NMA

PD

HD

pmol/min/mg.protein)

Control

PD

HD

19.61.4 14.41.0* 12.11.0* 125.610.1 95.45.4* 86.74.7*
1.60.3

1.40.4

1.50.4

7.7 2.3

6.31.6

5.21.4

21.31.5 16.31.3* 15.41.5* 142.412.3 92.47.8* 90.55.7*
1.70.4

1.80.4

1.40.3

9.6 3.1

8.72.9

7.83.0

Results are meanSEM of two separate experiments, each performed in triplicate.
HGEC: human glomerular endothelial cells; BAEC: bovine aortic endothelial cells.
*: P<0.05 compared to control.

88

Table 3: Plasma concentration of ADMA and SDMA in normal control, peritoneal
dialysis and hemodialysis patients.

ADMA

SDMA

(M)

(M)

Control

0.450.10

0.120.02

PD

2.160.27*

0.750.13*

HD

4.130.78*

1.410.19*

*P<0.01 compared to control.
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Study III: Studies of the effect of urea on L-arginine transport and endothelial nitric oxide
synthase activity
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SUMMARY
The mechanisms of reduced nitric oxide (NO) production in chronic renal disease
(CRD) patients is incompletely understood. Many metabolites that accumulate in CRD
may be involved. Urea, one of the end products of L-arginine that accumulates in renal
failure is conventionally considered to be innocuous, but our observations suggest that it
may have a role in reducing the activity of the L-arginine-NO-endothelial system. In this
study, we evaluate the effects of uremic levels of urea on L-arginine transport and nitric
oxide synthase activity in both human and bovine endothelial cells. This study included
both acute (6 hours) incubation and chronic (one week) incubation with synthetic
solutions containing uremic concentrations of urea.
Our experiments show that uremic levels of urea significantly inhibit L-arginine
transport but do not affect endothelial NOS activity (eNOS) after 6 hours incubation.
Using synthetic solutions which contain high levels of urea and some of the amino acid
concentrations found in uremic plasma, we again observed inhibition of L-arginine
transport with no effect on eNOS activity after 6h incubation. In addition to human
dermal microvascular endothelial cells, we have made similar observations in human
glomerular endothelial cells and bovine aortic endothelial cells. These findings suggested
a general effect of urea on L-arginine transport in vascular endothelial cells. The
inhibition of L-arginine transport into endothelial cells can be reversible after removing
urea from the cell medium. To study the mechanisms of the inhibition of L-arginine
transport, we added the urea directly with L-arginine into cell medium, and we found that
urea did not competitively inhibit L-arginine transport into the cells, but rather required a
period of several h pre-incubation to inhibit the y+ transporter. In a chronic study, after
one week incubation of endothelial cells with uremic levels of urea, L-arginine transport
was again inhibited but now we also observed that eNOS activity was inhibited, perhaps
secondary to intracellular arginine deficiency. The inhibition of L-arginine transport and
eNOS activity was not related to alterations in osmolarity of the medium.
These studies show that at least in vitro, a uremic level of urea has an impact on
the arginine-NO-endothelial system by reducing L-arginine transport into endothelial
cells, and in the long term (7d) is also able to inhibit NOS activity. The mechanism by
which urea inhibits L-arginine transport at the y+ transporter is not known but does not
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involve simple competition. It is possible that high BUN may be a contributory factor in
reduced intracellular substrate availability and consequent inhibition of eNOS activity in
the patients with end stage renal failure.

Key words: Urea, endothelial cells, Nitric Oxide, L-arginine, Chronic Renal
Disease, Transport, eNOS Activity
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INTRODUCTION
Nitric oxide (NO), generated from the terminal guanidino-nitrogen atoms of Larginine by a family of enzymes known as NO synthase (NOS), is an important
endogenous biological modulator with diverse physiological actions. NO controls
vascular resistance, blood pressure and platelet function and serves as a neurotransmitter,
and a host defense agent in the immunological system (1,2,3). In vascular smooth
muscle, NO stimulates production of cGMP, which promotes vasodilation by lowering
intracellular Ca2+ concentration and reducing sensitivity of the contractile proteins to Ca2+
(4, 5). Basal release of NO by endothelial cells contributes importantly to the
maintenance of normal blood pressure in the resting state and it has been demonstrated
that the L-arginine-NO pathway is impaired in some animal models and patients with
advanced hypertension (6,7,8).
Although the effect of chronic renal disease (CRD) on NO metabolism is
incompletely understood, our former clinical studies have found that total NO production
was decreased in CRD patients (8). We have also found that the plasma from some of
CRD patients contains factor(s) that significantly inhibit the endothelial nitric oxide
synthase (eNOS) activity in cultured cells (9). Total NO production is also markedly
decreased in end stage renal disease patients (ESRD) (10). Furthermore, we have shown
that the plasma from ESRD patients, contains factor(s) that inhibit both L-arginine
transport into endothelial cells and eNOS activity (11). This suggests that the reduced
total NO production seen in vivo reflects dysfunction of vascular endothelial cells and
reduced endothelial NO generation.
We have strong suggestive evidence that the accumulation of the endogenous
methylated L-arginine analog, asymmetric dimethyl L-arginine (ADMA), is partly
responsible for eNOS inhibition and that other unknown metabolites may also be
involved. None of the methylated arginines accumulate in renal failure in a sufficient
concentration to influence L-arginine transport, however. Urea is a protein metabolite
that accumulates in renal failure and is used conventionally to measure the severity of
renal impairment. Although urea was conventionally regarded as an innocuous
metabolite that accumulated in renal failure, recent evidence indicates that urea may
interfere with cellular metabolism and protein synthesis (12). In addition, several studies
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have demonstrated that urea inhibits transport of electrolytes and both cellular and
extracellular enzyme synthesis (13). Urea is a breakdown product of L-arginine by the
action of arginase. The synthesis of L-arginine and its subsequent conversion to Lornithine and urea is an essential metabolic pathway that serves to eliminate excess
nitrogen containing compounds from the body (14). Recently, one study has shown that
high levels of urea produce a dose-dependent, reversible inhibition of inducible NO
production in macrophages by a posttranscriptional mechanism and may be important in
macrophage dysfunction of uremia (15). Based on this evidence we reasoned that uremic
levels of urea may play a role in the inhibition of eNOS activity and NO production from
endothelial cells in ESRD.
In present study, we made synthetic media containing uremic levels of urea to
determine the effects of urea on L-arginine transport and NOS activity in human dermal
microvascular endothelial cells. In addition, some experiments were also conducted in
human glomerular endothelial cells and bovine aortic endothelial cells to study the
general effects of urea on L-arginine transport and NOS activity.
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METHODS
Materials: Human dermal microvascular endothelial cells (HDMEC) and
endothelium growth medium (EGM-MV) were obtained from Clonetics Corporation (San
Diego, CA). Human glomerular endothelial cells (HGEC) and CS-C growth medium
were obtained from Cell System Corp. (Kirkland, WA). The bovine aortic endothelial
cells (BAEC) were established by us in primary culture from thoracic aortas harvested
from the local abattoir. The following supplies and drugs were used: Minimum essential
medium (MEM, Life Technologies, Inc. Grand Island, NY); fetal bovine serum (FBS,
Atlanta Biologicals, Inc, Norcross, GA). [3H]L-arginine ( L-[2,3,4,5-3H] Arginine
monohydrochloride, 63.0Ci/mmol, Amersham Life Science, Arlington Hights, IL).
Monomethyl-L-arginine (L-NMA,Calbiochem-Novabiochem Corporation La Jolla, CA);
Urea and protein assay reagents (Bio-Rad Laboratories, Hercules, CA); Dowex 50WX8400, L-arginine and all other chemical reagents were obtained from Sigma Chemical Co.
(St. Louis, MO).
Cell culture: HDMEC (passage 4-7) were maintained in EGM-V media
containing 10 pg/ml human recombinant epidermal growth factor, 1g/ml
hydrocortisone, 50g/ml gentamicin, 50ng/ml amphotericin-B, 12g/ml bovine brain
extract and 5% fetal bovine serum. HGECs (passage4-7) were maintained in CS-C
medium and BAECs (passage 2-4) were maintained in DMEM + 10% FBS. All cells
were incubated at 37oC in a humidified atmosphere of 5% CO2 and 95% air and had
tested positive for Factor VIII and acetylated low density lipoprotein (LDL) uptake and
negative for smooth muscle alpha actin, confirming that they are pure endothelial cells. In
preparation for the experiments, cells were subcultured onto 12-well plates and once they
became confluent (usually ~5 days for HDMECs when seeded at a density of 7000/ cm2;
~7 days at a density of 5000/cm2 for HGEC and ~3 days at a density of 15000/cm2 for
BAECs), the culture medium was replaced with MEM containing synthetic media which
contained 20% FBS.
The composition of synthetic media I and II are shown in Tables 1 and 2.
Medium I was a simple solution containing electrolytes and urea in normal and uremic
concentrations, with variable glucose concentrations to maintain iso-osmolarity. Medium
II also contained amino acids which mimic free amino acid profile in the plasma of
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uremic patients and healthy controls (16,17), Initial time course experiments were done
and we found that cells remained completely viable when incubated for 6h but that some
cell detachment occurred at 24h and longer. Therefore, in all experiments in acute
studies with synthetic media, cells were incubated for 6h and then studied for arginine
transport or NOS activity. In chronic study, we used normal EGM-MV medium to
ensure that cells remained viable but added uremic levels of urea or iso-osmolar mannitol
for the 7d incubations.
Determination of L-arginine transport: Transport of L-arginine into endothelial
cells was measured by the method of Gazzola et al (18). Briefly, after 6h incubation with
synthetic cell medium, the medium was removed and the cells washed twice with KrebsHEPES buffer. Then 0.5ml Krebs-HEPES buffer containing 50M L-arginine with 2l
L- [3H]arginine (2 Ci) was added to each well. Transport was terminated by removing
the media and rapidly washing the cells three times with ice-cold phosphate buffer saline
solution (PBS) containing 10mM unlabeled L-arginine. The cells were then lysed with
0.5% Triton X-100 in 0.5M NaOH, and cell associated radioactivity was measured in a
liquid scintillation counter. The background was determined by incubating the cells in
parallel wells with Krebs-HEPES buffer containing 10mM unlabeled L-arginine and the
fraction of radioactivity associated with these cells was determined and subtracted from
each data point. Since L-3H-arginine content by the endothelial cells reached a maximum
after 5 minutes (details in the general method and study I), in all subsequent experiments,
measurement of L-arginine transport was performed at 3 minutes incubation time.
Determination of nitric oxide synthase activity: NOS activity was determined in
all cells by measuring L-[3H]arginine conversion to L-[3H]citrulline according to the
method of Davda et al (19), with modifications. Briefly, after 6 hours incubation, the
medium was removed and cells were incubated with 0.5ml Krebs-HEPES buffer
containing (in mM): 131NaCl, 5.5KCl, 2.5CaCl2, 1.0 MgCl2, 25.0 NaHCO3, 1.0
Na2HPO4, 5.5 D-glucose, 20.0 HEPES and 50M L-arginine/2l L-[3H]arginine (2Ci;
31.7 pmol arginine) for 1 hour at 370C. The experiment was terminated by removing the
medium and rapidly washing the cells three times with ice-cold phosphate buffer saline
solution (PBS) containing 10mM unlabeled L-arginine, then cells were solublized in
0.5ml 1% Triton X-100 and 50ul aliquots were taken for determination of total uptake of
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L-[3H]arginine in a scintillation counter. A portion of the cell homogenate (0.3ml) was
added to 0.7ml 50% Dowex 50WX8-400 (Na+ form) to remove unconverted L[3H]arginine. These samples were vortex mixed for 3 minutes, centrifuged at 2000g for 2
minutes, and the radioactivity of an aliquot (0.5ml) of the supernatant was measured in a
liquid scintillation counter to give the activity due to L-[3H]citrulline (details in general
methods and study I).
Measurement of cell protein: The total cellular protein was determined by the
Bio-Rad detergent method which uses a modification of the Lowry assay (20) with
bovine serum albumin as a standard.
Experimental protocol:
1. Studies of the acute effect of urea on L-arginine transport and eNOS activity after 6
hours incubation of the HDMEC with synthetic medium I and II.
2. Acute studies of the direct effects of added urea on L-arginine transport. HDMEC
were maintained in the normal EGM-MV medium until confluent when the normal
medium was removed. Uremic level of urea (25 mM) with 3H-L-arginine was added to
the assay buffer directly to study the effect of urea on L-arginine transport in HDMEC.
3. Acute studies to determine whether the effect of urea (after 6h incubation) on Larginine transport in HDMEC is reversible. After 6 hours incubation of HDMEC with a
high level of urea, the synthetic media were removed and replaced with normal medium
for 12 hours incubation, then the L-arginine transport was measured.
4. Studies on the chronic effects of urea on L-arginine transport and eNOS activity.
Either uremic level of urea or the same concentration of mannitol was added to the
normal cell medium to maintain the same osmolarity. The media was changed every
other day, and after one week incubation when cells were confluent, L-arginine transport
and eNOS activity were measured in 12 well plates. Experiments were repeated at least
three times, each time was triplicate. Individual numbers are given in the Table or Figure
legends. Results are expressed as mean  SEM. Statistical analysis was performed with
the use of Student’s unpaired t-test and one way ANOVA. Values of p<0.05 are
considered to be significantly different.
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RESULTS
Figure 1A shows that after 6 hours incubation with 25 mM urea solutions (media
I), L-arginine transport into HDMEC was significantly inhibited compared to cells
incubated in control medium. Similar observations were made with the second synthetic
medium which also contained some of the amino acids profiles seen in uremic plasma
(media II), as shown in Figure 1B. Since most of the transport is inhibitable with L-NMA
(open columns, Figures 1A and 1B), most of the L-arginine transport measured here is by
the y+ transporter system (21). In contrast, we found no impact on eNOS activity after 6
hours incubation either with media I or media II, compared to the normal controls (Figure
2A and Figure 2B), suggesting that any reduction in intracellular L-arginine availability
due to reduced transport over the 6h period of the study, was not sufficient to affect eNOS
activity.
We also measured the effects of urea on L-arginine transport and eNOS activity in
HGEC and BAEC, to determine whether the effect was generalized. After 6 hours
incubation with a uremic level of urea, the L-arginine transport was similarly inhibited in
both HGEC and BAEC, while the eNOS activity did not change either in HGEC or
BAEC (Table 3).
To study whether urea acts by competitive inhibition of the L-arginine transporter,
uremic level of urea (25 mM) with 50M L-arginine/ 2l 3H-L-arginine was added to the
assay buffer directly after the cells were confluent. And transport was measured over a 3
min period. Figure 3 shows that the direct addition of up to 25 mM urea to the assay
buffer did not competitively inhibit L-arginine transport into endothelial cells.
To determine if the inhibitory effect of urea on L-arginine transport in HDMEC
after 6 hours incubation with 25mM urea, is reversible, the medium containing 25mM
urea was removed and replaced with normal EGM-MV medium. After a further 12hours
incubation with regular medium, L-arginine transport was measured and as shown in
Figure 4, the inhibitory effect of urea on L-arginine transport in the endothelial cells was
totally reversed.
In the chronic study cells were incubated for 7 days with urea (25 mM) or the
same concentration of mannitol, added to the EGM-MV medium. Cells were confluent at
7 days and L-arginine transport and eNOS activity were then measured. As shown in
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Figure 5, after 7 days incubation with 25mM urea, the L-arginine transport rate was
similarly inhibited to the 6 hours incubation. In Figure 6, the eNOS activity was also
seen to be inhibited by 25mM urea after 7days, in contrast to the lack of effect at 6h
(Figure 2). These effects on L-arginine transport and eNOS activity were due to urea
since changes in the cell medium osmolarity with mannitol did not affect L-arginine
transport and NOS activity in endothelial cells.
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DISCUSSION
Hypertension is a very common complication in patients with end stage renal
disease (ESRD) and is often difficult to control. Several factors are involved in the
genesis of ESRD-induced hypertension (8, 22, 23, 24, 25) and one important mechanism
may be related to NO deficiency (22, 24). In our former studies, we have shown that
total NO production was decreased in ESRD patients and that factors in ESRD plasma
inhibited both endothelial nitric oxide synthase (eNOS) activity and substrate, L-arginine,
transport in cultured cells (study II).
Studies in our laboratory and others have found that the accumulation of
endogenous L-arginine analogues in renal failure, plays an important role in inhibition of
NO production and NOS enzyme activity (24). In plasma from both ESRD and CRD
patients, we found that the accumulation of the L-arginine analogue, asymmetric
dimethyl L-arginine (ADMA) is a marker, and is partly responsible, for the inhibition of
eNOS activity (studies 1 and 2). Other workers have shown that ADMA can be
transported into endothelial cells by the same transport system ( y+ transport system)
which is the major route of L-arginine transport (25). In our earlier work we found that
although the uremic concentration of ADMA (2 - 10 M) can inhibit eNOS activity,
these levels are too low to affect L-arginine transport, since competition was only seen at
pharmacological concentrations of ADMA (100M) (Study I). Thus, some other factor in
ESRD plasma must be responsible for the inhibition of L-arginine transport. We
speculate that inhibition of L-arginine transport in ESRD in the long-term could cause
intracellular L-arginine deficiency and lead to reduction of NO production although the
plasma concentration of L-arginine in ESRD patients is above the Km of the eNOS (26).
Of note, this y+ inhibitor is not present in sufficient concentrations in the plasma of CRD
patients to exert an inhibitory effect on L-arginine transport (study 1).
Urea is a well-known end product of protein metabolite that accumulates in renal
failure and is used conventionally to measure the severity of renal impairment. In ESRD
patients, the plasma concentration of urea is increased 5-10 times above normal while in
CRD patients with ~ 30 % residual renal function, BUN is only 2-3x normal. Although
urea was conventionally regarded as an innocuous metabolite that accumulated in renal
failure, there is renewed interest in urea as a potential cellular toxin. Urea may interfere
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with cellular metabolism, transport of electrolytes and also inhibit cellular and
extracellular enzyme synthesis (12,13). Furthermore, urea is a product of the breakdown
of L-arginine by the action of arginase (27). We therefore reasoned that the accumulation
of urea in ESRD patients may be related to the inhibition of L-arginine transport seen
with ESRD plasma.
Our data show that in the acute study, uremic level of urea 25 mM (~75 mg/dl
BUN) significantly inhibited L-arginine transport into endothelial cells after 6 hours
incubation. However, NOS activity did not change. In the media II, after adding different
amino acids to imitate some of the uremic amino acid profiles, we obtained the same
results as with media I. This suggests that in the short term study, urea can inhibit Larginine transport into endothelial cells but not sufficiently to affect NOS activity. This
inhibition of transport by urea is not related to the alterations of amino acid profiles in the
end stage renal disease. Since we made similar observations in human capillary
endothelial cells (HGEC) and bovine aortic endothelial cells (BAEC) as well as in the
human dermal microvascular endothelial cells (HDMEC), we consider that high
extracellular urea has a general, widespread effect on L-arginine transport in vascular
endothelial cells.
In our chronic study of the urea on the L-arginine transport and NOS activity,
after adding the uremic level of urea to the normal cell media for one week after splitting
the cells, we found that both L-arginine transport and eNOS activity were inhibited.
These effects of urea on L-arginine transport and NOS activity were not related to
alterations in osmolarity, because the addition of mannitol did not change the L-arginine
transport and NOS activity. We suggest that the eNOS inhibition is seen at 7days but not
6h, because it takes time for intracellular arginine levels to become sufficiently depleted
that substrate availability becomes rate limiting. These data have an important clinical
implication and suggest that high BUN may play a role in the pathogenesis of the
hypertension in ESRD patients. We also anticipate that when CRD becomes increasingly
severe, levels of BUN will also rise to values where L-arginine transport is inhibited.
Our present studies with artificial solutions are also consistent with the experiments with
ESRD plasma where hemodialysis led to a reduction in the L-arginine transport
inhibitory activity of uremic plasma, in parallel with a reduction in BUN (Study 2).
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Our studies further found that the inhibition of L-arginine transport by urea is
reversible after removing the urea from the cell medium. To study the mechanisms of the
L-arginine transport inhibition, we added the different concentrations of urea to the assay
buffer directly. We found that the inhibition of L-arginine transport by urea did not act
like ADMA, L-NMA and other methyl L-arginine analogues to compete with the Larginine transport through the y+ transporter system (25). Therefore, the effect of urea
may be related to the interactions between the urea and cell membrane and then affect the
structure of the y+ transporter system. To date, the cDNAs of two different y+ -like
carriers have been cloned (CAT-1 and CAT-2, for cationic amino acid transporter), from
both murine and human cells. At physiological pH, CAT proteins transport the basic
amino acids L-arginine, L-lysine, and L-ornithine. The apparent affinities of each CAT
protein are similar for all three substrates (29). Although high urea did not compete with
L-arginine for CAT protein, it may interfere with the cell membrane and affect this
transporter system. The detail mechanisms of the effect of urea on the y+ transporter
system need to be further studied.
In conclusion, we believe that urea may play a potentially important role in the
pathogenesis of the uremic syndrome, by contributing to the hypertension via inhibition
of L-arginine transport into endothelial cells and thus reducing eNOS activity. In
addition, high BUN may contribute to the immune dysfunction of ESRD by inhibiting the
NO production from macrophages (15) in the patients with end stage renal disease. Our
observations of the inhibitory effect of high level of urea on NO:L-arginine system not
only limited in HDMEC, but also in HGEC and BAEC. Therefore, these findings suggest
a general effect of uremic level of urea on the endothelial-NO system.
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Figure 1.

Control
L-NMA 5mM

200

Uremic medium

Control medium

Effect of uremic level of urea on the L-arginine transport in HDMEC. After
6 hours incubation with the cells, the L-arginine uptake was determined by
the addition of 50uM L-arginine/L-3H-arginine to the cells incubated with
Kreb-HEPES buffer in 3 minutes. L-NMA 5mM was added to some wells to
confirm specific L-arginine transport by the y+ pathway. Results are mean
SEM of three separate experiments, each performed in triplicate. * P<0.05
compare to control. A: incubation with Media I (25mM urea). B: incubation
Media II (25mM urea with uremic plasma amino acid profiles).
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Control Medium

Uremic Medium

Effects of uremic levels of urea on the NOS activity in HDMEC.
After 6 hours incubation with the cells, NOS activity was
determined by measuring the conversion rate of L-arginine to Lcitrulline over 60 min period. L-NMA 5mM was added in some
wells to confirm specific NOS activity. Results are mean  SEM of
three separate experiments; each performed in triplicate. A:
incubation with media I (25 mM urea); B: incubation with media II
(25mM urea with uremic plasma amino acid profiles)
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Effects of different concentrations of urea on L-arginine transport in human
dermal microvascular endothelial cells. Different concentrations of urea
were directly added to the assay medium and incubated for 3 minutes.
Results are mean SE of three separate experiments in triplicate.
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After incubating HDMEC with synthetic solutions containing with 25 mM
urea (urea medium) or 25 mM glucose (control medium) for 6 hours, the
regular EGM-MV medium was added to replace the synthetic solutions
and incubated for 12 hours. L-arginine transport was then measured in
HDMEC, by the addition of 50M L-arginine/L-3H-arginine to the cells
incubated with Kreb-HEPES buffer in 3 minutes. Results are mean SEM
of three separate experiments; each performed in triplicate.
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Effects of 25mM urea (uremic level), 10mM and 25mM mannitol on the Larginine transport in HDMEC. After one week incubation with the cells,
L-arginine transport was determined by the addition of 50M Larginine/L- 3H-arginine to the cells incubated with Kreb-Hepes buffer in 3
minutes. Results are meanSEM of these separate experiments; each
performed in triplicate. *: P<0.05 compare to the mannitol as a control
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Effects of 25mM urea (uremic level), 10mM and 25mM mannitol on NOS
activity in HDMEC. After one week incubation with the cells, NOS activity
was determined by measuring the conversion rate of L-arginine to Lcitrulline. Results are meanSEM of three separate experiments, each was
performed in triplicate. *: P<0.05 compare to the mannitol as a control.

112

Table 1: Synthetic medium I
Uremic medium

Control medium

(mM)

(mM)

117.0

117.0

KCl

5.4

5.4

CaCl2

1.8

1.8

MgSO4

0.8

0.8

NaHCO3

26.2

26.2

NaH2PO4

1.0

1.0

D-glucose

5.5

55.5

Urea

25.0

0.0

FCS

20%

20%

311

308

NaCl

Osmolarity
(mOsm)
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Table 2: Synthetic medium II
Uremic medium

Control medium

(mM)

(mM)

117.0

117.0

KCl

5.4

5.4

CaCl2

1.8

1.8

MgSO4

0.8

0.8

26.2

26.2

NaCl

NaHCO3
NaH2PO4
D-glucose
Urea

1.0

1.0

5.5

55.5

25.0

0.0

L-citrulline

0.05

0.025

L-arginine

0.10

0.10

L-glutamine

1.00

0.75

L-lysine

0.2

0.2

L-glycine

0.5

0.25

L-cystine

0.1

0.05

20%

20%

314

310

FCS
Osmolarity
(mOsm)

_____________________________________________
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Table 3: Effects of synthetic medium I on NOS activity and L-arginine transport in
HGEC and BAEC.
NOS activity

L-arginine transport

(pmol/min/mg.protein)
Control
HGEC Basic

16.41.1

L-NMA
BAEC Basic

2.40.7

Urea
14.91.7
2.60.7

20.32.1

21.52.4

2.91.0

2.80.8

L-NMA

(pmol/min/mg.protein)
Control

Urea

128.3 7.0

100.1 4.0*

11.9 3.8
138.311.4
10.7 2.1

9.6 2.7
99.710.0*
9.4 2.4

Results are meanSEM of two separate experiments, each performed in triplicate. P<0.05
compare to control.
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Study IV: Effects of urea on nitric oxide production, blood pressure and renal function in
conscious chronically catheterized rats.

116

SUMMARY
Urea is a protein metabolite and was conventionally regarded as an innocuous
product that accumulated in renal failure. However, recent evidence indicates that urea
may, in fact, interfere with cellular metabolism and protein synthesis. Also, urea may
interfere with transport of electrolytes and inhibit cellular and extracellular enzyme
synthesis. In our earlier cell culture studies, we found that plasma from uremic patients
inhibited both eNOS activity and L-arginine transport. The inhibition of L-arginine
transport is caused by the high plasma level of blood urea nitrogen (BUN). In synthetic
solutions with uremic levels of urea, after one week incubation with endothelial cells,
both the eNOS activity and L-arginine transport were inhibited.
We therefore conducted the present studies to see if 7days of high BUN in vivo,
would lead to a decrease in eNOS activity and consequent vasoconstriction and increased
blood pressure. We fed normal male adult rats with low nitrate food containing 30%
urea. After one week, the BUN increased about 4 times vs control and this increment
was maintained throughout a 24 hour cycle. The 24hour urinary NOx (nitrate and
nitrite) production (as a measure of total NO production), blood pressure and renal
function were measured. We found that high BUN did not reduce the 24hour urinary
NOx excretion, suggesting that total NO production was not inhibited by high BUN.
Furthermore, neither blood pressure nor renal hemodynamics were altered by urea
feeding. The pressor response to acute NOS inhibition with L-NAME was unaffected by
high BUN although the decreases in GFR, RPF and increase in RVR with L-NAME were
enhanced after 7 days of urea feeding.
In conclusion: we found that high plasma concentration of urea did not
noticeably lead to NO deficiency in rats with normal renal function. Further studies are
needed to evaluate the effect of high BUN on NO system in rats with progressive renal
functional insufficiency.

Key words: conscious rat, in vivo, urea, blood pressure, renal function, nitric oxide, NOx
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INTRODUCTION
Hypertension is an important cause of cardiovascular complications,
hospitalization and death in patients with ESRD (CRD) (1,2). In CRD patients who still
have residual renal function, hypertension is a major risk factor in acceleration of the
progression of CRD to ESRD (3,4). In ESRD patients, hypertension is also a major risk
factor that affects long-term renal replacement treatment (1,2,5). The mechanisms of
hypertension in CRD patients are very complex and incompletely understood and
hypertension is not optimally controlled (6,7,8).
Nitric oxide (NO), once known as a toxic environmental pollutant, is now
recognized as an important endogenous biological modulator with diverse physiological
actions (9, 10). Basal, constitutive release of NO by vascular endothelial cells plays an
important physiological role in the maintenance of normal blood pressure and vascular
tone. Conversely, relative NO deficiency leads to a rise in arterial pressure. It has been
demonstrated that the L-arginine: NO pathway is impaired in animal models and in some
patients with hypertension (11,12). Several studies have also reported that reductions in
NO production occur in CRD. For instance, renal insufficiency has been shown to cause
accumulation of endogenous NOS inhibitors, which can potentially depress NO
production in CRD. In addition, rats with renal mass reduction show reduced urinary
excretion of NO metabolites (total nitrates + nitrites) and diminished histochemically
detectable NOS in the remnant kidney, as well as reduced NOS activity, suggesting
reduced renal NO production (13,14). Furthermore, chronic administration of a NO donor
has been shown to retard progressive deterioration of renal function and structure in
experimental CRD (15). However, the mechanisms of reduced NO production in CRD
are not clear. In our series of cell culture studies we found that the plasma from ESRD
patients inhibited both the L-arginine transport into endothelial cells and the NOS
activity. These inhibitions are closely related to the accumulation of endogenous Larginine analogues (methylated L-arginine derivatives) and urea. In the cell culture study
of urea on L-arginine transport and NOS activity, we found that in short term incubation
of uremic levels of urea with endothelial cells (6 hours incubation), L-arginine transport
was inhibited but NOS activity did not change. However, in the chronic in vitro study,
after incubation for 1 week with a high concentration of urea, both the L-arginine
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transport and NOS activity were inhibited in the human microvascular endothelial cells
(studies I-III in this dissertation). Therefore, the inhibitory effects of uremic levels of urea
on L-arginine transport may lead to inhibition of eNOS activity, which may contribute to
the reduction of NO production and hypertension in ESRD patients in vivo.
In this study, we chronically fed normal rats a high urea diet to produce uremic
plasma concentrations of BUN. In this preparation, we studied the effects of uremic
levels of urea on total NO production, blood pressure and renal function in conscious rats
in comparison to the same animals under conditions of normal BUN.
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METHODS
Animal model: Conscious, chronically catheterized rats were used. Male SpragueDawley rats (350-450g) were obtained from Harlen Sprague-Dawley, Indianapolis, Inc.
The procedure for the rat catheterization was carried out using full sterile conditions and
under general anesthesia, using the short-acting barbiturate, Brevital (Eli Lilly & Co.,
Indianapolis). The induction dose was 50mg/kg ip, and, thereafter, 5-10mg/kg was given
iv as required. Tygon catheters were placed in the abdominal aorta and inferior vena ,
through the left femoral artery and vein, threaded under the skin by 16-G trocar and
exteriorized at the back of the neck, primed with a 1:1 solution of heparin (1000 IU/ml)
and dextrose (50%) and the ends were plugged with stainless steel pins. The urinary
bladder was catheterized via a suprapubic incision with a bladder cannula. The cannula
was then primed with neomycin and plugged with a stainless steel pin covered in silastic,
so that the rat can void normally through the urethra. After recovery from general
anesthesia, rats were returned to individual home cages and were able to move freely in
the cage. All of these catheterized rats were trained to accept handling, the activities in
the laboratory and to sit quietly in a restraining cage for several hours at a time. The first
renal function experiment was performed at least seven days after the initial surgery.
Experimental protocol: Figure 1 illustrates the complete protocol for this study.
Six male Sprague-Dawley rats were used. Rats were fed a low nitrate food (ICN:
AIN76C) for at least 3 days then a control 24h urine collection was made for
measurement of baseline 24hour urinary NOx production and protein excretion.. After
recovery from surgery, rats were maintained on low nitrate food for the duration of the
study. At least 7 days later, a renal function experiment was conducted measuring blood
pressure, renal hemodynamics and the plasma concentration of blood urea nitrogen
(BUN) in control (2 x 20 min collection periods). After completion of the measurements
with normal BUN, all rats received a diet of low nitrate containing 30% urea (urea food).
Rats were given 20g urea food, twice a day at 12 hour intervals for one week. This is an
adaptation of a previously published protocol which allows urea feeding to produced
elevated BUN in rats with normal renal function (16). In a pilot animal we determined
that BUN was elevated and stable at 6 h intervals over a 24 hour period (9113 mg/dl)
after 3 days on the high urea diet. Rats were placed in metabolic cage at days 5-6 on high

120

urea food, given 24h to recover and then a final renal function experiment was conducted
with control measurements and then the response to acute NOS inhibition was
determined (see below).
Measurements of mean arterial blood pressure and renal function: Renal
function experiments were performed as follows: Rats were placed in restraining cages.
For measurement of mean arterial blood pressure, the arterial catheter was connected to a
pressure transducer attached to a Maclab system (a multipurpose data recording and
analysis system when used with a computer) which allowed continuous measurement of
mean arterial blood pressure except during occasional blood sampling. The renal function
measurements included glomerular filtration rate (GFR) by measuring the renal clearance
of inulin, renal plasma flow (RPF) by measuring the clearance of p-aminohippuric acid
(PAH), filtration fraction (FF), renal vascular resistance (RVR) and sodium excretion. To
measure renal function, the bladder pin was removed and a silastic tube with a sidearm
was attached to the bladder catheter for collection of urine. After washing the bladder
with sterile water to ensure complete recovery, the bladder was flushed with air just
before the end of each urine collection, to obtain complete collection of urine, into preweighed cups. An iv (via the femoral vein) infusion of 0.9% NaCl containing tritiated
inulin (5Ci/ml) and (PAH, 1%) was given at a rate of 0.5 l/min/kg body weight. This
rate approximately equals urine flow in this preparation, so it is a non-expanding infusion
rate. After an equilibration period of ~80 minutes, to allow for plasma inulin and PAH
concentrations to reach a plateau, two exactly timed 20-minute urine collections with
midpoint arterial blood samples (300 l). One minute before the end of each period, the
bladder was flushed with air to assure complete collection of urine. The blood sample
was centrifuged and plasma removed for analysis. The red blood cells were return to the
rat after re-suspension with sterile 0.9% NaCl. Then, acute systemic NOS inhibition was
achieved with iv L-NAME (10mg/kg; a supermaximal pressor dose in this preparation
(17) and 10 min later 2 x 20 min clearance measurements were again made.
Measurements of urine volume, the plasma and urinary tritiated inulin activity,
the plasma and urinary concentrations of PAH, sodium, potassium, the plasma total
protein concentration and the blood hematocrit: Urine volume was determined
gravimetrically. Measurement of tritiated inulin activity was performed using 10l
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samples of urine or plasma plus 3 ml Scintillation fluid and 0.3 ml water in a Packard
scintillation counter. PAH concentration was measured colorimetrically (18) using 120 l
of sample with 40l of each reagent including a coupling reagent (N-1-Napthyl-ethylene
diamine dihydrochloride) which turns color upon binding PAH. Samples are read at
540nm and compared to standards to determine PAH concentration. The plasma or
urinary concentrations of sodium and potassium were measured using a flame photometer
with lithium chloride as internal standard. The plasma total protein concentrations were
measured by refractometers and the blood hemotocrit was measured in a micro -capillary
reader. GFR was calculated by measuring the clearance of inulin and the RPF by
measuring the clearance of PAH. The RVR, urinary excretion of sodium and potassium
(UNaV and UKV) and the fractional excretion of sodium (FENa) were calculated from the
above values (calculations given below).
Measurements of 24 hour nitrate and nitrite: The NOx (nitrate+ nitrite) levels of
urine samples were measured with Griess assay according to Stuehr (19) using the nitrate
reductase enzyme, which reduced NO3 to NO2. The enzyme was produced by E. Coli
cultured under anaerobic conditions and in a nitrate reductase-inducing medium for 14h.
The generated NO2 was detected and quantitiated by the Greiss reaction. Briefly, 125ul of
samples plus 100ul of HEPES/ammonium formatting mixture in a 1:1 ratio was made,
then 25ul of nitrate reductase was added, and incubated for 60 minutes at 370C in a
shaking water bath. During the incubation all of NO3 was reduced to NO2 as shown by
complete conversion of NO3 standards following incubation with the enzyme. After the
incubation, samples were then centrifuged 2000 rpm X 15 minutes. 100ul of this
supernatant is added to a 1:1 (V/V) mixture of Griess reagent (1.0% sulfanilamide in
0.1% naphthylethylene diamine ) in 96 well plates for 10-15 minutes at room temperature
and the absorbance is determined at a wavelength of 543nm spectrophotometrically in an
ELISA plate reader. A standard curve is constructed using known concentrations of
sodium nitrite and nitrate over the linear range of the assay (5-500uM). Details of this
method have been published previously by us (20).
24 hours urine protein assay: The urinary protein concentration was determined
by the Bradford assay (21) which involves addition of 10l of sample and 100l of
Biorad dye reagent (this reagent turns color upon binding to protein). Samples are read at
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540nm and compared to standards to determine concentration of protein with the bovine
albumin as a standard (details in General Method for cellular protein assay).
Calculations: Whole Kidney GFR (ml/min) was calculated as:
GFR= Uinulin X V/ Pinulin
Where Pinulin and Uinulin are plasma and urine concentrations of inulin, respectively; and V
is urine flow rate (ml/min).
RPF (ml/min) was calculated from the clearance of PAH divided by renal extraction
(assumed to be 0.85 in the awake rat (22):
RPF= (UPAH X V/ PPAH) X 0.85
Where PPAH and UPAH are plasma and urine PAH concentrations, respectively.
FF=GFR/RPF
Where FF is filtration fraction
RVR (mmHg/ml/min) was calculated as:
RVR=(BP-5)/ RPF/ (1-Hct)
Where BP is mean arterial blood pressure; Hct is hematocrit; and mean venous blood
pressure was assumed to equal 5 mmHg at all times.
FENa (%) was calculated as:
FENa= [(UNA X V)/(GFRXPNa)] X100
Where PNa and UNa are plasma and urine sodium concentrations, respectively.
Twenty four hour urinary excretion measurements were calculated as:
UxV= Ux X V
Where Ux is urine concentration of either sodium, NOx or total protein.
Results are expressed as mean  SEM. Statistical analysis was performed with the
use of Student’s paired t-test between the pre- and post-treatment (normal and high BUN
and baseline and acute NOS inhibition in the high BUN group). Values of p<0.05 are
considered to be significantly different.
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RESULTS
Effect of urea feeding on BUN, urinary total protein excretion and urinary NOx
excretion. As shown in Figure 2 (top panel), 7 days of feeding rats with low nitrate food
containing 30% urea, produced ~ 4X rise in BUN compared to control. As shown in the
second panel, the 24hour urinary volume significantly increased with high BUN, despite
a substantial fall in the urinary excretion of Na and fractional Na excretion (3rd, Figure
2). This marked rise in urine flow reflects the osmotic diuretic effect of the urea load,
since as shown in the bottom panel of Figure 2, Uosm reached maximal values in the urea
fed rats. We measured 24h UNOXV as an index of total body NO production and, contrary
to our hypothesis, we saw no fall in UNOXV after 7 days of high BUN. In fact, as shown
in Figure 3, UNOXV increased moderately, as did 24h urinary protein excretion, probably
due to an osmotic effect (see Discussion).
Effect of urea on mean arterial blood pressure and renal hemodynamics: Figure
4 (upper panel) show that a sustained rise in BUN for a week did not affect the mean
arterial blood pressure in these conscious rats, compared to their blood pressure under
baseline conditions of normal BUN. As shown in the lower panels (solid histograms), 7
days of uremic levels of BUN had no effect on the baseline RVR, RPF or GFR, with
renal function remaining normal in these rats throughout the study period.
Effect of acute NOS inhibition on BP and renal function after 7 days of high
BUN: As shown in Figure 5, acute administration of the NOS inhibitor, L-NAME,
produced a significant increase in BP in rats with elevated BUN. We did not measure the
response to acute NOS inhibition in these rats under control conditions of normal BUN,
since we did not want to make any interventions that might disturb the endogenous NO
system. However, we have previously reported in several studies that a similar rise in
BP occurs in normal rats with control levels of BUN when given acute L-NAME
(17,23,24,25).
As shown in the lower panels of Figure 5, acute L-NAME produced a marked rise
in RVR (a fall in RPF, not shown) with a more modest reduction in GFR. This is a
similar pattern of response seen in normal control rats studied in this same preparation
and reported by us previously (17,23-25). The only difference in the response to acute
NOS inhibition seen in rats with high BUN was that the increase in urinary sodium
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excretion observed in normal control rats (17,23-25) was totally blocked by the high
uremic level of BUN, since urine flow was already markedly elevated due to the urea
feeding. We presume that this reflects another facet of the osmotic diuretic effect of the
high BUN in animals with normal renal function .
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DISCUSSION
Urea is a breakdown product of L-arginine, formed mainly in the liver by the
action of arginase (26). The synthesis of L-arginine and its subsequent conversion to urea
is a major metabolic pathway that serves to eliminate nonessential nitrogen-containing
compounds from the body. The urea once formed, is not further metabolized and is
distributed in the total body water and excreted by the kidney (27). In health and under
conditions of relatively constant intake of protein, the plasma and urine levels of urea
may serve as an index of renal function, dietary protein intake, and hydration in the adult
mammal.
In end stage renal disease (ESRD), the plasma concentration of urea increases ~5
to 10 X above control, due to loss of renal clearance. Although previously regarded as an
innocuous uremic metabolite, recent evidence indicates that urea interferes with cellular
metabolism and protein synthesis (28), transport of electrolytes and also synthesis of a
number of enzymes (29). We have also previously observed that plasma from patients
with ESRD significantly inhibits L-arginine transport into cultured vascular endothelial
cells after 6 hours incubation (30). Furthermore, after 7 days incubation, both L-arginine
transport and eNOS activity is inhibited in cultured endothelial cells grown in a high
urea environment (31). We speculate that in the long term, this inhibitory effect of Larginine transport into endothelial cells by high extracellular urea may cause intracellular
L-arginine deficiency and thus inhibit endothelial NO production. Of note, it has
previously been reported that high urea levels inhibit iNOS activity and NO production
from stimulated macrophages (32); an effect which may account for some of the
immune-suppression of advanced renal failure.
To test the direct effect of urea on the L-arginine: NO system, we designed
experiments in vivo to evaluate the effects of elevated BUN on NO production (by
measuring the 24 hour NOX production = NOX excretion), blood pressure and renal
function. To avoid interference of NOx ingested in the diet, which confounds
interpretation of UNOXV data (33), rats were fed with low nitrate food. Because of this
precaution we think it likely that the 24h UNOXV reported here gives a valid, qualitative
index of the total NO production. Contrary to our hypothesis 24h UNOXV did not fall as a
result of sustained high BUN, suggesting that total NO production (from all tissue
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sources), is not impaired by a uremic blood level of urea, per se. In fact, there was a
small rise in 24h UNOXV (24h urinary protein excretion) with high BUN. We are
reluctant to conclude that this means increased NO production with urea feeding,
however, in view of the major renal tubular effects of such a large urea load. Since these
animals with high BUN, have normal renal function, they are undergoing a profuse
osmotic diuresis during the 7 days of urea feeding. Both NOX and filtered plasma
proteins normally undergo significant proximal reabsorption (20) and it is likely that the
increases in 24 hour urinary protein and NOx excretions reflect a “washout” effect
secondary to the proximally acting osmotic diuretic action of excess urea. We would
predict that plasma NOX would fall accordingly as a result of high BUN, although we did
not make this measurement in the present studies.
Of course, 24h UNOXV reflects total NO production and since the NO from eNOS
is likely to be a very small fraction of this total, UNOXV may have little predictive power
of direction changes in eNOS activity. We also measured blood pressure since NO
generation from eNOS provides a powerful vasodilatory tone (23-25), and eNOS
deficiency in rats is associated with hypertension (34). In our conscious, chronically
catheterized rat preparation, high plasma urea for 7 days did not affect the baseline blood
pressure. Since these are paired studies in an optimum, unstressed model for study of BP
regulation, we are confident that BP was not altered by BUN. Furthermore, the pressor
response to acute NOS inhibition in the high BUN state was robust, and similar to that
seen in several earlier studies by us, in rats with normal BUN (17,23-25). One possible
explanation of these findings is that in vivo, high BUN has no impact on eNOS
production or eNOS dependent regulation of vascular tone and BP. Interpretation of in
vivo observations is complicated, however, since many compensatory mechanisms are
operative which may mask an effect.
We also found that high BUN had no impact on baseline renal hemodynamics or
on the response to acute NOS inhibition, which again may suggest that in the normal rat,
high BUN has no impact on eNOS activity. Of course, the same concerns apply
regarding possible masking compensatory responses. The only difference that we saw in
response to acute NOS inhibition in rats with high BUN, was that urea totally blocked the
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natriuresis caused by L-NAME. Most likely, this reflects the osmotic diuretic action of
urea, overwhelming the natriuretic effects of a pressor dose of L-NAME.
In conclusion, we found that high plasma concentration of urea did not
perceptibly inhibit the L-arginine: NO system in vivo. Specifically, total NO production,
blood pressure and renal hemodynamics were unaffected in rats with normal renal
function and elevated BUN. Further studies are needed to evaluate the effect of high
BUN on the NO system in rats with renal functional insufficiency.
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Figure 2. Effects of uremic level of BUN (top panel) on urinary Volume (second panel),
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*: P<0.05 compare to control.
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Effects of inhibition of NO synthesis with L-NAME on blood pressure (BP,
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filtration rate (GFR, third panel) and urinary sodium excretion (U NaV
bottom panel) in rats fed with urea. *: P<0.05 compare to Baseline.

137

GENERAL DISCUSSION
Nitric oxide produced from vascular endothelial cells plays an important role in
maintaining the blood pressure and vascular tone in physiological situations (Moncada, et
al., 1995; Kone and Baylis, 1997; ). Several studies both in animal models and human
have demonstrated that NO deficiency is related to hypertension (Baylis and Vallance ,
1996; Moncada et l.,1993). Hypertension and other cardiovascular complications are the
major causes of hospitalization and death in patients with chronic renal diseases.
Hypertension is also an important risk factor for accelerated progression of chronic renal
disease to end stage renal failure (National High Blood Pressure Education Program:
Working Group. 1995; Buckalew, et al., 1996; Lazarus, et al., 1997). So far, the
mechanisms of hypertension are not completely understood and hypertension in these
patients is not optimally controlled (Galla, et al., 1996; Converse, et al., 1992). Since the
kidney is one of the major sources for the synthesis of L-arginine, the substrate for NO
production, the reduction of renal mass in CRD may affect NO production by limiting
substrate availability. Also, since many L-arginine analogs that accumulate in renal
failure may act competitively with L-arginine to inhibit NO synthesis. Therefore, it is
possible that high prevalence of hypertension in chronic renal disease is related to NO
deficiency.
The overall objective in my present studies is to investigate alterations of NO
derived from vascular endothelial cells in chronic renal disease. These studies include in
vitro cell culture and in vivo animal experiments, designed to follow up our clinical
studies which indicate a reduction in total NO production in patients with end stage renal
disease. Specifically, my studies investigate whether NO deficiency is related to the NO
enzyme activity inhibition and/or reduced substrate availability in vascular endothelial
cells. We also studied the effects of urea, conventionally regarded as an innocuous
metabolite which accumulates in renal failure, on the endothelial NO: L-arginine system
both in cell culture studies and animal experiments.
In the studies on patients who still have residual renal function, we investigated the
direct effect of plasma from CRD patients on substrate (L-arginine) transport and
endothelial nitric oxide synthase activity in cultured human endothelial cells. We found
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that plasma from CRD patients had no effect on the L-arginine transport after 6 hours
incubation with human dermal microvascular endothelial cells. However, the NOS activity
was inhibited by plasma from some but not all CRD patients. We demonstrated that we
were measuring eNOS activity and not inducible NOS (iNOS) in this type of endothelial
cells in additional studies with dexamethasone. Pre-treatment of cells with
dexamethasone, which inhibits transcription of iNOS, can inhibit NOS activity stimulated
by LPS, IFN- and IL-1, but did not affect NOS activity after incubation with plasma
from CRD patients for 6 hours. Comparing the levels of eNOS activity in CRD patients,
we found no relationship between NOS activity of plasma and the primary diseases. Since
all of these CRD patients have been taking various antihypertensive drugs, we considered
the possibility of interference by medication on eNOS activity of plasma. These CRD
patients were on various antihypertensive drugs which include diuretics (furosemide and
HCTZ), calcium-channel blockers ( aminodipine and diltiazem), -receptor blocker
(metoprolol) and angiotensin II converting enzyme inhibitors (enalapril, captopril and
lisinopril). There is evidence that these drugs either have no impact on NO production (receptor blocker) (Saijonmaa, et al., 1997) or actually increase NO production (diuretics,
calcium channel blockers and angiotensin II converting enzyme inhibitors) ( Wiemer, et
al., 1994; Zhang, et al., 1999) in vascular endothelial cells. Therefore, the inhibition of
eNOS activity by plasma from some CRD patients is apparently related to some general
feature of chronic renal disease.
To further study the mechanisms of the low NOS activity in some CRD patients,
we measured the plasma concentrations of the L-arginine analogues ADMA and SDMA
with HPLC. It has been reported that these methyl L-arginines may competitively bind
NOS and inhibit NOS activity (Vallance, et al., 1992). In our study, we found that the
average plasma levels of ADMA were not statistically different when compared to the
normal control although variability was high. However, after separating the 11 CRD
patients into two subgroups based on the level of NOS activity, we found that the patients
showing low NOS activity had very high plasma concentrations of ADMA, whereas
those with normal plasma NOS activity had normal levels of ADMA. This suggests that
high plasma levels of ADMA may be responsible for the inhibition in eNOS activity. To
study further the direct effect of ADMA on NOS activity in vascular endothelial cells, we
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used a synthetic medium containing different concentrations of ADMA. We found that
1M ADMA does not affect the NOS activity. However, 2.5M ADMA, a concentration
equivalent to the plasma concentrations of ADMA in CRD patients with low eNOS
activity, can inhibit NOS activity in endothelial cells after 6 hours incubation, and that as
the concentration of ADMA increased in the synthetic medium, NOS activity was further
inhibited. This study directly demonstrated that high levels of ADMA in extracellular
fluid could play an important role in the inhibition of eNOS activity in endothelial cells.
Because we used only 20% human plasma to incubate with the cells, the final
concentration of ADMA in this incubation solution (even from patients with high plasma
ADMA levels) should be lower than 1M. Therefore, the inhibition of NOS activity by
uremic plasma must also be related to other factors although ADMA is a marker for these
unknown inhibitory factors. The mechanism of high plasma levels of ADMA in some
CRD patients is not clear. It has been suggested that plasma ADMA increase in renal
failure due to decreased renal clearance (Vallance et al., 1992). Comparison of renal
functions based on BUN and creatinine clearance with the plasma levels of ADMA in
these CRD patients, however, did not demonstrate any relationship. A recent study
reported that some patients with chronic renal diseases have an eNOS gene
polymorphism and the authors speculate that this difference in eNOS gene may be related
to the renal function deterioration (Yokoyama, et al., 1998). Thus the question remaining
is why are ADMA levels high, and does this high level of ADMA in some CRD patients
affect the progression of chronic renal disease to the end stage of renal failure? Also,
does high plasma ADMA predispose to cardiovascular complications? These questions
need to be further studied.
Concerning the role of SDMA, we found the plasma levels of SDMA are
significantly higher in CRD than the control and there is no relationship in the CRD
patients with NOS activity of plasma. This is consistent with a recent report that SDMA,
unlike ADMA, can not inhibit eNOS activity directly but SDMA can significantly inhibit
substrate (L-arginine) transport into endothelial cells (Closs, et al., 1997). So in the long
term, high plasma concentration of SDMA in CRD may cause intracellular L-arginine
deficiency in vascular endothelial cells and lead to endothelial NO deficiency. Therefore,
we think that the mechanisms of inhibition for eNOS activity in vascular endothelial cells
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by plasma from some CRD patients are complex; that ADMA is an important marker for
this eNOS inhibition, but that some other factors may also be involved in inhibiting NO
production by affecting the enzyme activity and/or L-arginine substrate availability.
In the study on the NO:L-arginine system in patients with end stage renal disease
(ESRD), NO deficiency has been suggested to contribute as a volume-independent cause
of hypertension in ESRD (Reyes, et al., 1994). Our lab has conducted carefully
controlled clinical studies in ESRD patients on both PD and HD and have reported a
reduction in total NO production compared to subjects with normal renal function
(Schmidt, et al., 1996; 1999). Our assumption in this clinical study was that diminished
total NO production reflected, at least in part, a reduction in "vasoactive NO" produced
by vascular endothelial cell eNOS. The present study was designed to directly test this
possibility, providing evidence which implicates uremia as a cause of eNOS inhibition.
We found that factor(s) in plasma from both peritoneal dialysis (PD) and hemodialysis
(HD) patients reduced NOS activity in cultured vascular endothelial cells by ~30%
compared to control. Since these cultured cells are only exposed to 20% plasma for 6h, it
seems likely that in vivo, the eNOS-inhibitory actions of uremic plasma are even more
pronounced. We observed a NOS inhibitory action of uremic plasma in both dermal
microvascular and glomerular capillary endothelial cells of human origin, as well as in
bovine endothelial cells from the aorta. The NOS inhibitory effect of uremic plasma
should be widespread throughout the circulation, which in turn implicates NO deficiency
from eNOS as a cause of increased peripheral resistance and thus elevated blood pressure
in ESRD.
Having described the phenomenon, we also investigated the cellular mechanism
by which uremic factor(s) in ESRD plasma inhibits eNOS. Our original hypothesis,
which prompted our earlier clinical studies, was that ESRD represents a state of arginine
(i.e. substrate) deficiency. This hypothesis was based on the fact that arginine utilized by
eNOS is derived both from the diet and from that made endogenously, mainly by the
kidney (Morris, et al., 1992; Reyes, et al., 1994). In ESRD a lack of functional renal
mass compromises this latter source of arginine generation which could lead to arginine
deficiency and impaired NOS. We and others have reported low-normal to mildly
subnormal plasma arginine values in ESRD patients (Reyes, et al., 1994; Schmidt, et al.,
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1995; 1996). However, the plasma arginine levels in ESRD always remain well above
the km of the eNOS enzyme (Bredt, et al., 1996) which should not, therefore, lead to
substrate-dependent falls in NO production. These apparently discrepant observations
could be reconciled if uremic factors inhibit arginine transport into the endothelial cell,
thereby creating low, rate-limiting intracellular arginine levels. For this reason we
investigated the effect of uremia on arginine transport and determined that indeed, uremic
plasma does inhibit arginine entry into endothelial cells. The majority of endothelial cell
arginine uptake is via the L-NMA inhabitable y+ transporter (Bogle, et al., 1992), and
transport via the y+ transporter is decreased by ESRD plasma. When we consider that
both renal production of arginine and arginine transport into endothelial cells are reduced
in ESRD, this suggests that the normal to mildly sub-normal values of plasma arginine
encountered in ESRD do indeed reflect relative arginine deficiency; a view supported by
the observation that orotic acid levels (a marker for arginine deficiency) are increased in
uremia (Daniewska-Michalska, et al., 1993).
Plasma from ESRD patients also acutely (within 6h) inhibits eNOS activity. This
inhibition may be due to intracellular substrate depletion and/or NOS inhibitory factors
present in uremic plasma. There are a number of endogenous arginine analogs that can
inhibit NOS activity when they are present in sufficient quantities and there is evidence
that these accumulate in ESRD. For example, plasma concentrations of asymmetric
dimethylarginine (ADMA) increase in renal failure patients, possibly in concentrations
that inhibit NO synthesis (Vallance, et al., 1992), although this is controversial
(Pettersson, et al., 1997; Marescau, et al., 1997; Anderstam, et al., 1997). In our studies
we have found increases in plasma ADMA in both PD and HD patient plasma, in a
concentration range where NOS activity would be affected. It is likely that the NOS
inhibitory activity of uremic plasma is due to arginine analogs, since we were able to
reverse the inhibition of NO production (measured by NOX levels) with excess unlabelled
arginine in the cell incubation medium. This finding has important therapeutic
implications since this observation provides a mechanism for the protective effect of
chronic arginine supplementation as a method of lowering BP and preserving renal
function in renal disease (Chen, et al., 1992; Reyes, et al., 1993).
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It has been reported that some types of human endothelial cells can express both
the constitutive eNOS and the inducible NOS (iNOS) when appropriately stimulated
(Liang, et al., 1994). Hemodialysis provokes the release of cytokines which are iNOS
stimulators (Amore, et al., 1997) and we were concerned that some of the remaining NOS
activity seen in endothelial cells incubated with HD patient plasma, might reflect iNOS
activity. However, pre-treatment of vascular endothelial cells with glucocorticoids such
as dexamethasone prevents synthesis of iNOS and thus prevents cytokine-stimulated
increases in iNOS activity (Radomsk, et al., 1990; Simmons, et al., 1996). Since
dexamethasone pre-treatment had no effect on NOS activity in cells incubated with
normal control, pre- or post HD patient plasma in our study, we conclude that in these
studies only eNOS activity is operating in the cultured endothelial cells. Of importance,
this also shows that post-HD plasma contains some eNOS inhibitory activity, suggesting
that NOS inhibitory activity in ESRD plasma was not completely removed by HD. All
these patients have been using similar antihypertensive drugs as the CRD patients, These
drugs either have no impact on endothelial NO production ( -receptor blocker)
(Saijonmaa, et al., 1997) or increase the endothelial NO production (diuretics and
angiotensin II converting enzyme inhibitors) ( Hoechst, et al., 1994; Zhang, et al., 1999).
So the eNOS inhibition in both PD and HD patients is directly related to the end stage
renal failure.
Concerning the endogenous inhibitors of eNOS activity and L-arginine transport,
studies in our lab and others have found that the accumulation of endogenous L-arginine
analogues play a very important role for the inhibition of the NO production and NOS
enzyme activity (Vallance, et al., 1992). In addition to inhibiting eNOS activity, the Larginine analogue, asymmetric dimethyl L-arginine ADMA, is transported into
endothelial cells with the same transport system by which most of L-arginine is
transported, the y+ transport system (Closs, et al., 1997). However, we found that the
plasma concentration of ADMA in the patients with ESRD was not high enough to
inhibit the L-arginine transport (study I), so factors other than ADMA must be involved
in the inhibition of L-arginine transport into endothelial cells by the plasma from these
ESRD patients (see below). The inhibition of L-arginine transport into endothelial cells
would have implications by causing intracellular L-arginine deficiency and then lead to
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the reduction of NO production even though the plasma concentration of L-arginine in
ESRD patients is above the Km of NOS (Bredt, et al., 1996).
Urea is a well known end product of protein metabolism that accumulates in renal
failure and is used conventionally to measure the severity of renal impairment. In the
ESRD patients, the plasma concentration of urea is increased 5-10 times above control.
Although urea has been conventionally regarded as an innocuous metabolite that
accumulated in renal failure, there is a renewed interest in urea as a potential cellular
toxin. Urea may be involved in interfering with cellular metabolism, transport of
electrolytes and also inhibit cellular and extracellular enzyme synthesis (Rajagopalan, et
al., 1963; Lim, et al., 1995). Furthermore, urea is produced from the breakdown of Larginine by the action of arginase (Reyes, et al., 1994). So it is possible that the
accumulation of urea in ESRD patients is related to the inhibition of L-arginine transport,
eNOS activity and NO synthesis.
Our in vitro data showed that in the acute study of urea on L-arginine transport
and eNOS activity, an artificial solution containing a uremic level of urea 25mM
(~75mg% BUN) significantly inhibited the L-arginine transport into endothelial cells
after 6 hours incubation. However, NOS activity did not change. In media II, which also
contained amino acids to imitate the uremic amino acid profile, we obtained the same
results as those in the media I. Thus, in the short term, high urea inhibited the L-arginine
transport into endothelial cells but did not affect the NOS activity. This inhibition of
transport by urea is not related to the alterations of amino acid profiles in the end stage
renal disease. Since we repeated these observations in HDMEC, HGEC and BAEC,
these data suggested a general effect of urea on L-arginine-NO-endothelial system. We
further found that the inhibition of L-arginine transport by urea is reversible within 12h
after removal of the urea from the cell medium. To study the mechanisms of the Larginine transport inhibition, we added different concentrations of urea to the assay buffer
directly, and found that urea does not competitively inhibit L-arginine transport. This is
in contrast to ADMA, L-NMA and other methyl L-arginine analogs when compete with
L-arginine for transport through the y+ transporter system (Closs, et al., 1997). So the
effect of urea is indirect and may be related to the interactions between urea, the cell
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membrane and changes in the structure of the y+ transporter system. Details of this
mechanism of the effect of urea on the y+ transporter system needs to be further studied.
In our chronic in vitro study of urea on L-arginine transport and NOS activity, we
incubated confluent cells in an uremic level of urea for one week. Here we found that not
only was the L-arginine transport inhibited but eNOS activity was reduced as well. These
effects of urea on L-arginine transport and NOS activity were not related to alterations of
osmolarity, because the addition of equi-osmolar mannitol did not change the L-arginine
transport and NOS activity. These data suggest an important clinical implication of urea
in the pathogenesis of the hypertension in ESRD patients. It is possible that long term
interactions between uremic levels of urea and the endothelial cells in ESRD patients
may cause deficiency of NO production by the inhibition of L-arginine transport and
subsequently, reduced NOS activity. Therefore, we believe that urea, a compound
considered to be innocuous that accumulates in renal failure, may have potentially
important implications in the pathogenesis of hypertension.
To investigate the direct effect of urea on the NO: L-arginine system, we designed
an in vivo experiment as our last study to evaluate the effects of urea on NO production.
We measured the 24 hour urinary nitrate and nitrite excretion as a marker of total NO
production, 24 hour urinary protein, blood pressure and renal function in rats with normal
renal function. To avoid the interference of the NOx (nitrate and nitrite) from the diet,
rats were fed with low nitrate food. In our preliminary experiment in which rats were fed
low nitrate food containing 30% urea ad lib, we found the rats failed to reach uremic
concentrations of BUN. We changed the feeding time and fed the rats twice a day, 2
hours each time. When rats are fed a high urea direct using this protocol, the plasma
concentration of urea rises to 5 times higher than control and can be maintained at a
constant level for 24 hours even in rats with normal renal function. Therefore, we used
this model to study the in vivo effect of urea on the L-arginine: NO system.
In these in vivo studies, high plasma level of urea did not inhibit NO production,
measured by 24 hour urinary NOx excretion. The urinary volume in the urea-fed rats
increased 4 times compared to before urea feeding, and in fact total 24 hour urinary NOx
excretion was higher after urea feeding. These rats have normal renal function and the
high urea diet caused an "osmotic diuresis" which may be responsible for the small
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increase in 24 hour urinary NOx excretion in urea-fed rats. High plasma level of urea did
not affect the blood pressure in normal rats, and after giving L-NAME, the pressor
response in urea-fed rats is the same as in normal controls. Several possibilities may exist
to explain these results. One is that, with normal renal function, there may be some
substances that block the inhibitory effect of urea on L-arginine transport or/and eNOS
activity. Another possibility is that the animal with normal renal function can somehow
compensate for the inhibition of endothelial NO system by the high level of urea, to
maintain the normal blood pressure. There was no impact of high BUN on the baseline
renal function and acute L-NAME produced similar decreases in GFR, RPF and increase
in RVR, to that reported earlier for normal rats (Baylis, et al., 1990; Zatz and Baylis,
1998). It is difficult to know how to interpret this in the context of renal NO generation
but is not suggestive of reduced renal NOS activity in rats with high BUN. Therefore, in
this in vivo experiment, high plasma concentration of urea did not significantly inhibit the
L-arginine: NO system in conscious rats with normal renal function.
In conclusion, in our series of studies, we found that the clinical finding of
reduction of total NO production in chronic renal disease is related at least partly to the
inhibition of endothelial nitric oxide synthase activity and substrate availability ( Larginine transport into endothelial cells) even though the plasma concentration of Larginine is above for the Km of eNOS. Dialysis can partially improve the inhibition of Larginine transport but did not change the inhibition of eNOS activity by the uremic
plasma. In vitro exogenous excess L-arginine can reverse the inhibition of NO production
by uremic plasma. This reversal of inhibition provides an important clue in how to
correct the deficiency of NO synthesis in patients with chronic renal disease. The
inhibition of NOS activity is closely related to the high plasma levels of endogenous Larginine analogs which are produced by protein metabolism and accumulated in renal
failure. However, many other substances are also involved in the inhibition of NO
production by affecting NOS activity and L-arginine transport. Urea, which has been
conventionally regarded as an innocuous metabolite that accumulates in renal failure, was
shown to play an important role in the inhibition of NO synthesis in our cell culture
experiments. It inhibits both the L-arginine transport (in 6 hours and one week
incubation) and eNOS activity (one week incubation). The inhibition of L-arginine
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transport by urea is not by simple competition with the y+ transporter system and this
inhibition can be reversed after replacing the uremic medium with normal cell culture
medium. Although we did not find a direct inhibitory effect of high urea in vivo on the
NO production, we believe that normal renal function is very important for maintaining
and/or compensating the normal vascular endothelial NO- L-arginine system and
systemic hemodynamics. Further studies are needed to evaluate the effect of high BUN
on NO system in rats with progressive renal functional insufficiency.
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